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Abstract 
Cyclic peptide ligands are a promising molecular format for the development of therapeutics. 
They combine some of the advantages of large protein therapeutics (high affinity and specificity) and 
of small molecule drugs (accessibility to chemical synthesis and low immunogenicity). With phage 
display, large combinatorial libraries of more than one billion mono- and polycyclic peptides can be 
developed and screened against virtually any target. During phage affinity selections, the physical link 
between phenotype (encoded peptide) and genotype (phage DNA) allows the identification of 
enriched peptide binders by sequencing of the phage vector DNA. Based on these concepts, our 
laboratory has established a robust chemistry in which phage displayed peptides containing two or 
three cysteines are cyclized or bi-cyclized with thiol-reactive linkers. This procedure has been 
generally applied for the isolation of potent and selective (bi)cyclic peptide ligands with therapeutic 
potential. The isolation of binders with optimal properties is highly dependent on the possibility to 
generate (bi)cyclic peptide libraries with high structural diversity and on the ability to thoroughly 
decode the phage selection output. In my PhD work, I developed new methods to generate large and 
structurally diverse libraries and to decode more efficiently phage selected peptides.  
In my first project, I explore the cyclization of peptides with two chemical bridges as a method 
to provide rapid access to phage-encoded libraries with high scaffold diversity. To this end, a range of 
twelve structurally diverse chemicals were tested for thiol-reactivity and phage compatibility. 
Subsequently, peptide libraries of the format XCXnCXnCX (X = random amino acid, C = cysteine, n 
= 3 or 4) were cyclized with six of these chemical linkers and panned against the protease plasma 
kallikrein. The selection yielded inhibitors with remarkable affinity (sub-nM KI), target selectivity 
(>1000-fold) and proteolytic stability (t1/2 in plasma > 3 days) despite a relatively small molecular mass 
(~ 1200 Da). 
In the second project, I developed phage-encoded libraries of small cyclic peptides in order to 
identify ligands that have the potential to be orally absorbed. A major challenge for the generation of 
such library is the usually low diversity of compounds due to the limited number of amino acids. In 
this work, we addressed this limitation by taking advantage of a recently discovered peptide 
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cyclization reaction in which the thiol of a cysteine is ligated with the N-terminal amino group using 
a chemical reagent. Unlike other cyclization strategies involving bridges between two amino acid side 
chains (e.g. two cysteines), this method maximizes the ratio between the number of target-interacting 
amino acid side chains and the number of peptide bonds. We applied this strategies to two phage-
encoded peptide libraries of four and five amino acids (XXXC and XXXXC) that were cyclized with 
eight chemical linkers yielding a collection of more than 1.3 million compounds. Panning the libraries 
against the two disease targets plasma kallikrein and coagulation factor XIa yielded ligands with 
single-digit micromolar affinity. 
In a third project, I developed a strategy to bypass the bacterial infection step in phage display. 
Bacterial infection is usually crucial for the propagation and identification of enriched clones by DNA 
sequencing. However, mutations or chemical modifications of the phage coat proteins, which are 
commonly used in phage-encoded cyclic peptide libraries, sometimes lead to decreased infection rates 
and therefore compromise the entire procedure. Consequently, there is an interest for developing 
methods in which this step could be completely omitted. Using next generation sequencing, I could 
prove that essentially all phage particles of a sample could be decoded by directly sequencing DNA 
from phage particles. In addition, the coverage of sequences was comparable to the one obtained when 
plasmid DNA from cells infected with wild-type phage was sequenced. 
Key words: Phage display, peptide library, bicyclic peptides, macrocycles, next-generation 
sequencing. 
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Résumé 
Les peptides cycliques sont un format prometteur de molécules thérapeutiques. Ils allient à la 
fois les avantages des protéines thérapeutiques, à savoir une excellente affinité et spécificité pour leurs 
cibles, et les propriétés favorables des petites molécules puisqu’ils sont facilement synthétisés et sont 
peu immunogéniques. En utilisant la technique du phage display, de larges banques contenant 
plusieurs milliards de peptides peuvent être créées et criblées sur des cibles d’intérêt. Pendant les 
sélections de phage, il existe un lien physique entre le phénotype (le peptide encodé) et le génotype 
(l’ADN codant du phage) ce qui permet l’identification des ligands peptidiques sélectionnés et 
enrichis grâce au séquençage de leur ADN. En se basant sur ces concepts, notre laboratoire a établi 
une réaction chimique avec laquelle les peptides exposés à la surface des phages peuvent être cyclisés. 
Ces peptides contiennent généralement deux ou trois cystéines à des positions fixes qui peuvent réagir 
avec un réactif de liaison bivalent ou trivalent. Cette procédure a été utilisée pour l’isolation de 
peptides (bi-)cycliques ayant une bonne affinité et un fort potentiel thérapeutique. La capacité de 
notre laboratoire à isoler des ligands ayant des propriétés optimales est fortement dépendante de notre 
faculté à produire des banques contenant des composés ayant une large diversité de structures. Un 
autre paramètre important consiste en notre habilité à parfaitement décoder les séquences d’ADN des 
peptides sélectionnés. Au cours de mon doctorat, j’ai travaillé sur ces deux aspects de la technologie 
du phage display au travers de trois projets qui sont brièvement décrit dans les paragraphes suivants.  
Un premier objectif de ma thèse était d’évaluer une nouvelle façon de cycliser les peptides avec 
deux ponts chimiques. Cette méthode a le potentiel de générer rapidement de large banques de 
peptides cycliques ayant une grande diversité de structures. Pour ce faire, une sélection de douze 
réactifs de cyclisation ont été testés afin de déterminer leur réactivité avec les groupements thiols et 
leur compatibilité avec les phages. Par la suite, des banques de peptides, exposés sur des phages et 
disposant d’un format XCXnCXnCX (avec X = acide aminé randomisé, et n = 3 - 4), ont été cyclisées 
avec six de ces réactifs de liaison puis criblées sur une cible d’intérêt, la protéase plasma kallikrein. La 
sélection de phage a mis à jour des ligands avec une affinité excellente (jusqu’à moins d’un 
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nanomolaire), une bonne sélectivité pour la cible (> 1000 fois) et une borne résistance à la protéolyse 
(t1/2 > 3 jour dans du plasma) bien qu’étant de faible poids moléculaire.  
Dans mon deuxième projet, j’ai développé des banques de petits peptides cycliques encodés par 
des phages afin d’identifier des ligands ayant le potentiel d’être absorbés oralement. Un défi majeur 
pour la création de telles banques reste généralement leur faible diversité due au nombre limité 
d’acides aminés. Nous avons remédié à ce problème en profitant d’une nouvelle réaction de 
cyclisation récemment implémentée par notre laboratoire. Elle fonctionne via la connexion d’un 
réactif de liaison au groupement thiol d’une cystéine située en aval du peptide, suivie d’une deuxième 
réaction avec le groupement amine du N-terminus. A la différence d’autres stratégies de cyclisation 
basées généralement sur des ponts moléculaires entre deux chaines latérales d’acides aminés (par 
exemple deux cystéines), cette approche maximise le rapport entre le nombre d’acides aminés 
interagissant avec la cible et le nombre de liaisons peptidiques. Nous avons appliqué cette stratégie à 
deux bibliothèques de phage contenant quatre ou cinq acides aminés (XXXC ou XXXXC) qui ont été 
cyclisées avec huit réactifs de liaison. Par conséquent, une collection de plus d’1,3 milliard de 
composés a été créée. Des ligands ayant une affinité proche d’un micromolaire ont été identifiés lors 
de sélections de phage contre la plasma kallikréine et le facteur de coagulation XIa. 
Dans mon dernier projet, j’ai développé une stratégie pour contourner l’étape d’infection 
bactérienne habituellement indispensable au phage display. Cette étape est normalement cruciale 
pour la propagation et l’identification des clones enrichis lors du processus de sélection par 
séquençage ADN. Cependant, certaines mutations ou modifications chimiques des protéines de 
capside du phage, qui sont communément utilisée dans les banques de peptides bicycliques, peuvent 
parfois diminuer fortement la capacité des phages à infecter leur hôte et par conséquent 
compromettre la totalité de la procédure. Ainsi, il serait intéressant de développer une méthode avec 
laquelle le matériel génétique des phages pourrait être séquencé sans nécessairement avoir besoin 
d’être injecté dans une bactérie. En utilisant le séquençage haut débit, nous avons pu prouver que la 
quasi totalité des virions présents dans un échantillon donné pouvait être décodée en séquençant 
directement l’ADN simple brin contenu dans les phages. D’autre part, la sensibilité de la méthode est 
comparable à celle obtenue avec les procédures standards où l’ADN plasmidique double brin est 
extrait des bactéries infectées par les phages.  
Mots clés : phage display, peptides bicycliques, macrocycles, librairie de peptides, séquençage haut-
débit. 
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1.1?– Cyclic peptides therapeutics 
?????? ??????????????????????????????????????????
Peptides are often defined as chains of approximately 3 to 50 amino acids, which is the 
commonly accepted boundary between proteins and peptides1. In recent years, peptide therapeutic 
have gained increasing attention from the pharmaceutical industry due to their potent and specific 
mode of action as well as their low inherent toxicity. Today, around one hundred peptide therapeutics 
are used in the treatment of a large variety of diseases. Interestingly, more than 40 of the approved 
peptide-based drugs are cyclic or polycyclic.  
Several methodologies have been used to cyclize peptides such as head-to-tail, head-to-side 
chain, side chain-to-tail, or side chain-to-side chain2 (Figure 1). In most cases, head-to-tail cycles are 
generated through amide bond or ester bond formation. By contrast, a wide range of chemistry can 
be applied for cyclizations involving side chains as for example disulfide bridging of cysteines, 
thioether bond formation, lactamization, etc. Moreover, innovative cyclization methodologies have 
also enabled the generation of polycyclic peptides3.  
 
Figure 1. The four possible synthetic approaches used to constrain peptides into macrocycles: 
head-to-tail, head-to-side chain, side chain-to-tail or side chain-to-side chain. Adapted with per-
mission from2, reprinting license nr. 4047091488316, copyright © 2011 Nature Publishing Group. 
Cyclic peptides offer numerous advantages in therapeutic applications compared to linear 
peptides4. First, their limited conformational flexibility reduces the entropic penalty upon binding 
which leads to higher binding affinity. Similar to proteins and antibodies, they can potentially bind to 
their targets with subnanomolar affinities. This can also be attributed to their intermediate size of 0.5 
to 5 kDa that affords large surface of interaction with their target. These specific contacts also 
minimizes the risk of off-target side-effects, which is considered one of the greatest advantage of 
peptides over small molecules. Another advantage of cyclic peptides is that the scaffolding of 
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macrocycles can lock them into a particular shape or secondary structure that can favor the 
interactions with specific binding surfaces5. For example, peptide stapling is an approach that consists 
of locking short peptides in their bioactive alpha-helical conformation by covalently linking the side 
chain of two amino acids6. This has been particularly useful for targeting protein–protein interactions 
that are mediated by α-helices, enhance their cellular uptake and their resistance towards proteolytic 
degradation. Finally, macrocyclization renders peptides less sensitive to proteolytic cleavage by 
reducing the likelihood of cleavage by both endo- and exo-peptidases7. This has the effect of 
increasing their stability in systemic circulation as compared to linear peptides. 
Apart from these differences, cyclic peptides also share all the favorable properties of their 
linear counterparts (Table I). They are associated with lower cost of production compared to 
antibodies and other protein-based therapeutics8. Over the second half of the 20th century, the 
generation of therapeutic peptides has been revolutionized by the emergence of solid phase chemical 
synthesis allowing the automated generation of peptides with high yields. Today, the method has 
evolved into a major technique and is compatible with thousands of amino acid building blocks, 
coupling reagents, etc., which facilitates complex peptide modifications, conjugations, or cyclizations. 
Furthermore, due to their small size and their biochemical nature, peptides display a lower risk of 
immunogenicity than large biologics and are usually not associated with the accumulation of harmful 
metabolites in the body as observed with small molecule drugs9. Finally, several studies have pointed 
to a correlation between smaller ligand size and greater tissue penetration, which offer peptides 
another advantage over protein-based therapeutics8.  
properties small molecules cyclic peptides 
biologics/anti-
bodies 
size10 < 0.5 kDa 0.5 to 5 kDa 5 Da to 200 kDa 
target specificity11 low high high 
typical potency11,12 nM to μM range pM to nM range fM to nM range 
membrane permeability11,13 good rare non-existent 
oral availability9,13 usually good usually poor never observed 
accumulation of harmful metabolites14 frequent rare rare 
immunogenicity9 rare rare frequent 
production costs15 rather low rather low high 
Table I. Summary of the strength and weaknesses of cyclic peptides as compared to small 
molecules and biologics. 
 Despite these demonstrated qualities, several challenges remain in the development of cyclic 
peptide drugs. Poor oral bioavailability is certainly one of their main limitations10. This can be 
imputed to the fact that peptides often are not resistant to pancreatic proteases or membrane 
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permeable (Table I). Today, several approaches are being evaluated to increase pancreatic stability as 
well as the diffusion or active transport of peptides through the gut epithelium. These include the use 
of smaller and more constrained peptide formats, N-methylation of the peptide backbone, as well as 
innovative formulation strategies13. Another problem is that intraveinously (i.v)-injected peptides 
undergo a fast renal clearance due to their small size and usually have a short half-life16. Methods for 
increasing the in vivo half-life of peptides and proteins have been extensively studied in the past few 
decades. These strategies include fusion or conjugation to serum proteins17–20, non-covalent binding 
to serum proteins21–23, or conjugation to polymers with large hydrodynamic radii24,25.  
?????? ????????????????????????????????????????
Owing to their excellent properties, more than 40 cyclic peptides have made their way to the 
therapeutic drug market26. The vast majority of them are directed against extracellular targets because 
of the typically poor cell permeability27. Among these, nearly all are derivatives of natural products 
that are indicated for the treatment of a variety of pathologies including infections, cancer and 
metabolic diseases. Although most of the approved cyclic peptide therapeutics are monocyclic as for 
instance the oncology drug octreotide and the immunosuppressant cyclosporine, a handful of 
polycyclic peptides are also used in the clinic. Some successful examples of these two categories will 
be discussed in the following paragraphs.  
The oncology drug octreotide and its derivatives (lanreotide, vapreotide and pasireotide) are a 
successful family of monocyclic peptide therapeutics. Indeed, octreotide (sandostatin, Novartis) is 
one of the best-selling cyclic peptide drug as it accounts for $1.6 billion of sales in 201628. Octreotide, 
which was first launched in 1988, is indicated for the treatment of acromegaly, carcinoid tumors and 
other types of gastrointestinal and pancreatic tumours29. It is a disulfide cyclized octapeptide that acts 
by blocking the release of hormones such as the growth hormone via the inhibition of G-protein-
coupled somatostatin receptors. As often experienced with cyclic peptide drugs, octreotide was shown 
to have a modest half-life of 90 to 120 min after subcutaneous administration. However, improved 
formulations of octreotide and its derivative lanreotide were recently introduced as for example 
octreotide long-acting release, lanreotide sustained release and lanreotide autogel30. Because of these 
innovations, a single administration every 14 or 28 days is required.   
Cyclosporin A (CsA) is another famous example of monocyclic peptide-based drug with 
exceptional pharmacokinetic parameters. The molecule was first isolated in 1970 from the fungus 
Tolypocladium inflatum. The immunosuppressive effect of CsA was discovered one year later in a 
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screening test on immune suppression performed by Hartmann F. Stähelin at Sandoz31. Currently in 
clinical use for the treatment of various pathologies (organ transplants management, rheumatoid 
arthritis, keratoconjunctivitis sicca etc.), CsA is also one of the strongest segment of the peptide 
market with $1.9 billion annual sales in 201532. It is well known for having a remarkable oral 
availability estimated between 10% and 60%13. Although the formulation clearly had an effect on its 
bioavailability, several structural properties of CsA were shown to affect its absorption as for example 
the cyclic backbone, the presence of N-methylated amino acids, the lipophilicity or the existence of 
four hydrogen-bonded amide NH protons. These features have considerably inspired the de novo 
design of orally available cyclic peptides. 
Polycyclic peptides have also been evaluated as potential drug candidates. For instance, 
Vancomycin and its derivatives (telavancin, dalbavancin and oritavancin) are polycyclic 
antibacterials broadly applied for the treatment of gram positive infections33. By binding to the D-
Ala-D-Ala target, these drugs block the transpeptidation of peptidoglycan precursors in the gram 
positive bacterial cell wall. In particular, the ability of vancomycin and its derivatives to interact with 
a molecule as small as a dipeptide underlined the importance of the high conformational constraint 
imposed by the three macrocyclic rings. Due to their efficacy against methicillin-resistant 
Staphylococcus Aureus (MRSA), they have been utilized for many years as “last resort” therapies for 
patients that were not responsive to other antibacterials. However, this trend is now changing because 
of the appearance of new resistant strains that necessitate novel therapeutic approaches such as the 
use of polymixins, which are another class of cyclic peptides. 
While the structure of vancomycin is not exclusively peptidic, polycyclic peptides composed of 
only natural amino acids have been exploited in the clinic. For instance, linaclotide is a 14-amino acids 
peptide cyclized through three disulfide bonds that is currently used by patients with chronic 
constipation and irritable bowel syndrome. As a result of its constrained conformation, the peptide is 
highly resistant to proteolysis and can be orally administered while not orally available. Indeed the 
target of linaclotide is guanylate cyclase C, an enzyme located on the surface of intestinal epithelial 
cells. By activating its target, the drug triggers a signaling pathway that generate abundant fluid 
secretions into the lumen, thereby increasing colonic transit. 
? ?
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1.2?– In vitro evolution of cyclic peptides 
?????? ??????????????????????????????
In the last ten years, several cyclic peptides that reached clinical trials were developed de novo 
using methods based on in vitro evolution26. This involves the generation of combinatorial libraries 
whose size and structural diversity are crucial in order to select lead candidates with desirable 
properties. Typically, in vitro evolution of cyclic peptide follows three different steps34,35. First, a 
combinatorial library of peptides is created and cyclized. For this step, the development of methods 
that maintain a one-to-one linkage between the phenotype (cyclic peptides) and the genotype 
(encoding sequence of DNA or mRNA) has greatly contributed to the development of large 
collections of compounds containing several trillion (1012) of variants. Second, the encoded repertoire 
of peptides undergoes a Darwinian selection process in which molecules with the most desirable 
properties (in most cases, affinity, specificity or stability) are isolated. Ultimately, the sequence of the 
selected peptides are determined using DNA sequencing strategies such as Sanger or Next Generation 
Sequencing (NGS). In the following section, some examples of successful approaches for the in vitro 
evolution of cyclic peptide are presented. In the interest of brevity, the discussion will be restricted to 
technologies that have brought cyclic peptides into clinical trials; namely phage display and mRNA 
display.  
Phage display is a technique that appeared in the mid-80’s and was the first in vitro display 
system to be established36. A short introduction of the method is given in this paragraph. However, 
the principles of phage display as well as the associated selection of peptide macrocycles are further 
described in the section 1.2.2. The most commonly used procedure relies on filamentous phage 
display such as M13 or fd. The libraries are generated by means of plasmidic collections that are 
transformed into phage competent E.coli. Peptide-tagged phage are subsequently assembled, released 
from bacteria and subjected to affinity selection against an immobilized target (Figure 2). The size of 
the libraries is usually limited by the transformation efficiency, resulting in diversities comprised 
between 108 and 1010 variants35. In the case of cyclic peptides, the most common approach is to encode 
peptides bearing an even number of cysteines that are either oxidized37 (Figure 3a) or cyclized with a 
chemical linker38,39. Peginesatide is the only cyclic peptide developed by phage display that has been 
approved by the Food and Drug Administration (FDA)26. It consists of a 45 kDa PEGylated 
erythropoietin mimicking peptide approved for the treatment of chronic kidney disorder associated 
anemia40,34. The drug was withdrawn from the market in 2012. 
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Figure 2. Schematic representation of a standard cycle of pIII phage display selection. DNA 
sequences encoding combinatorial libraries of peptides are cloned into a phage vector, in frame 
with phage coat protein III (pIII). Peptides are then displayed in 5 copies at the surface of the phage 
particles as pIII fusions. The phage-encoded library undergoes an affinity-selection against an 
immobilized target. Isolated binders are eluted and re-amplified in host E.coli cells. The procedure 
can be repeated several times before sequencing and identification of the selected clones. 
As already mentioned, the production of large phage-encoded libraries is strongly dependent 
on cell transformation efficiency which limits their size to a few billion compounds. In comparison, 
translation of the peptides in vitro circumvents this problem and enables larger diversity of 1013 to 
1014 molecules35,41. In order to maintain the nucleic acid encoding, the linkage between phenotype and 
genotype must then occur directly during translation. Such a strategy has been implemented for the 
display of a peptide on its coding mRNA (Figure 4). To do so, puromycin, a broadly used antibiotic 
that causes premature chain termination during ribosomal translation, is covalently attached to the 
3’- end of an mRNA strand. The peptide library is then ribosomally synthesized using a reconstituted 
in vitro translation system. At the end of the translation, puromycin is able to react with the peptide 
at the stop codon position which establish the covalent linkage between the mRNA and displayed 
peptide. The generated library can then be subjected to several rounds of affinity selection against an 
immobilized target and hits are identified by reverse-transcription of the RNA and consecutive DNA 
sequencing. 
Several cyclic peptide formats have been selected by mRNA display. For instance, Robert et al. 
efficiently cyclized mRNA-encoded peptide by reacting the two α-amino groups of a lysine and of the 
peptide N-terminus with disuccinimidyl glutarate (DSG)42 (Figure 3b). The library was then used in 
a selection against the signaling protein Gαi1 in which a binder with low nanomolar dissociation 
constant (Kd = 2.1 nM) was identified43. In order to evolve ligands with better serum stability, they 
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also tried to apply a proteolytic pressure prior to affinity selection44. With this approach, they isolated 
a cyclic peptide with around 100-fold better stability in serum while retaining high affinity for Gαi1 
(Kd = 9 nM).  
 
Figure 3. Examples of encoded cyclic libraries. a) Traditional cyclization of phage-encoded 
peptides by oxidation of two cysteines. b) Cyclization using the reaction of DSG with a mRNA-
encoded peptide displaying two primary amines. c) Cyclization of mRNA-encoded peptides by 
crosslinking two cysteines with α,α’-dibromo-m-xylene. d) Cyclization of mRNA-encoded 
peptides by spontaneous reaction of a chloroacetamide group with the thiol of a cysteine. Reprinted 
with permission from45, reprinting license n°4124691074190, copyright © 2015 Elsevier Ltd. 
Another strategy for cyclizing mRNA-encoded peptide libraries is to react bivalent thiol-
reactive compounds with peptides bearing two cysteines. This reaction was shown to be quantitative 
in aqueous buffers46 and Szostak et al. proved that it was compatible with in vitro translation systems 
and mRNA display47,48 (Figure 3c). They managed to create a library of more than 1013 peptides 
containing both natural and non-natural residues49. The incorporation of non-natural amino acids 
was made possible because of the tolerance of certain aminoacyl tRNA synthetases for analogues of 
proteinogenic residues. A selection against thrombin yielded an inhibitor with 1.5 nM affinity. The 
therapeutic peptide RA101495 was developed in a similar fashion. It inhibits the cleavage of the 
complement factor C5 into C5a and C5b and is currently under evaluation in a phase I trial for the 
treatment of paroxysmal nocturnal hemoglobinuria.  
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Figure 4. Schematic Illustration of a particular case of mRNA display. The RaPID system 
developed by Suga and coworkers. With this strategy, multiple non-canonical amino acids can be 
incorporating using flexizyme or Flexible in vitro translation (FIT). The library of peptide is 
ribosomally synthesized from the mRNA pool conjugated to puromycin. The mRNA is then 
reverse transcribed and the library is subjected to affinity-selection against an immobilized target. 
cDNAs encoding the hit compounds are re-amplified by PCR and transcribed for the next round 
of panning. Ultimately, the enriched peptides are identified by NGS. Reprinted (open access) 
from41, this article is available under the terms of CC-BY 3.0 license. 
Cyclization of mRNA displayed peptides can also be achieved via the incorporation of 
unnatural amino acids acting as chemical handles for cyclization. In order to be able to load these 
residues on tRNA, Suga et al. evolved an RNA-based catalytic tool called Flexizyme49 (Figure 4). With 
the flexible in vitro translation (FIT), a chloroacetamide functional group is conjugated to the α-
amino group of tryptophan or tyrosine and can be displayed on a mRNA-encoded peptide. 
Immediately upon translation, this group reacts spontaneously and intramolecularly with a cysteine 
forming a thioether bond50,51 (Figure 3d). With this method, Suga et al. identified several ligands to 
disease-relevant targets including ubiquitin ligase52 (Kd = 0.6 nM), Akt2 kinase53 (IC50 = 92 nM), and 
deacetylase SIRT254 (Kd = 3.7 nM). Subsequently, they commercialized their idea by founding the 
company Peptidream. Using their technology, Peptidream has successfully brought a cyclic peptide 
to clinical phase I for immune-oncology-related therapies54. 
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Phage display was described for the first time in 1985 by G.P. Smith36. In his study, he 
demonstrated that an exogenous protein can be expressed on the surface of a M13 phage coat protein 
III (pIII). To do so, Smith inserted a DNA sequence coding for a part of the EcoR1 enzyme on the 5’ 
end of the gene III of the phage, creating an N-terminal fusion protein. After showing that the 
introduced sequence was properly exposed on the phage capsid, he could prove that the modified 
virions retained their infectivity and ability to propagate. Consequently, his work revealed one of the 
main characteristics of phage display which is the linkage between the phenotype (peptide displayed) 
and the genotype (DNA code). 
The discovery of Smith was quickly associated with in vitro evolution of proteins and peptides. 
To this aim, DNA coding for randomized combinatorial libraries of peptides or proteins is inserted 
into the genome of a bacteriophage and expressed at the surface of a phage coat protein. The linkage 
between phenotype and genotype enables the isolation and identification of ligands through an 
iterative process of selection involving infection of bacteria and re-amplification of the phage (Figure 
2). In 1990, McCafferty et al. successfully selected phage-displayed antibody fragments with desired 
properties55. Since then, monoclonal antibodies (mAbs) are the class of therapeutic molecules that has 
benefited the most by far from phage display technology developments56,57. Adalimumab was the first 
phage-selected antibody reaching the market in 2002. It is a fully human antibody developed by 
Cambridge Antibody Technology (Now MedImmune/AstraZeneca) to block the interaction between 
Tumor Necrosis Factor α and its receptors. Adalimumab is commercialized under the name of 
humira and is currently indicated for the treatment of Rheumatoid arthritis, psoriatic arthritis and 
Crohn's disease58. In 2016, the annual sales of humira reached the value of $16 billion 59. 
Since the early developments of phage display, a variety of bacteriophage, such as filamentous 
phage, T7 and lambda have been exploited for in vitro selection. Among them, the filamentous phage 
(f1, fd and M13) are by far the most common because they represent excellent cloning vehicles60. Their 
genome is composed of genes coding for five different coat proteins that are located on a circular 
single-stranded DNA (ssDNA) of about 6400 base pairs. Almost all of these proteins have been used 
for phage display but pIII and pVIII are the most frequent. Approximately 2800 copies of pVIII, also 
called major phage coat protein, are arranged around the phage ssDNA and constitute its main body. 
Peptides displayed on the N-terminus of pVIII protein are limited to five or six amino acids because 
longer ones were shown to interfere with phage replication61. Unlike for pVIII, long polypeptides, 
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such as antibody fragments, can be displayed on pIII without impairing phage propagation. pIII is 
present in five copies at one end of the phage and plays a role in bacterial infection by interacting with 
the F pili and TolA receptor62.  
 
Figure 5. Schematic presentation of different types of phage display systems. In the type 3+3 
and 8+8, a wild type version of pIII and of the other coat proteins is provided by a helper phage (not 
represented here). In the type 33 and 88, the wild type version of pIII is directly encoded on the 
phage vector. Reprinted with permission from63, copyright © 2010 American Chemical Society. 
Additionally, phage display systems can be categorized by the number of peptides exposed on 
phage surface63. This parameter can strongly influence avidity effects during selections and can be 
modulated accordingly. On the one hand, multivalent systems can help to select binders from naïve 
libraries, as it enhances the capture of phage with suboptimal binding affinities. However, on the other 
hand, it can be a drawback during affinity maturation procedures when strong binders are desired. 
This specificity depends on the chosen phage coat protein: more than 2800 peptides are exposed on 
the virion particles when using pVIII display but only 5 when using pIII display (Figure 5). Another 
strategy employed to decrease the valence is to co-express the engineered coat protein with the wild 
type counterpart. This can be achieved in two ways (Figure 5): by transfecting a phage vector co-
expressing the wild type and engineered version of the coat protein (88 and 33 systems) or by using a 
phagemid system with helper phage (8+8 and 3+3 systems).   
Practically, phage peptide libraries are created by inserting a DNA coding for a randomized 
peptide or protein fragment into a double stranded phage vector. This involves a PCR with primers 
containing degenerated codons, for example NNK (N = A,T,C,G ; K = T, G), to avoid the 
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overrepresentation of the most common amino acids. Alternatively, a more rational and controlled 
randomization can be adopted in order to display desirable or favored amino acids. These strategies 
can be applied using oligos containing define tri-nucleotide codon content. This step is usually 
followed by subsequent ligation into the phage vector and electroporation into phage competent 
E.coli. This last step limits the achievable diversity to 107 – 1010 transformants which is often much 
inferior to the theoretical diversity.  
?????? ???????????????????????????????????
The first reported cyclic peptides identified during a phage selection were isolated from a 15-
mer linear peptide library64. Peptides containing pairs of cysteines were enriched suggesting that they 
probably had been selected in a disulfide cyclized format. The disulfide bond formation most likely 
takes place in the oxidizing environment of the bacterial periplasm or after release of the phage 
particles in the oxygenated culture medium. These observations encouraged the design of a second 
generation of phage-encoded peptide libraries in which a central randomized sequence is flanked by 
two fixed cysteine residues37. The first studies conducted with these libraries confirmed the selective 
advantage offered by cyclization. For instance, a screen against platelet glycoproteins with a 
hexapeptide library (CX6C, C = cysteine, X = any canonical amino acid), led to the identification of 
cyclic ligands with dissociation constants in the nanomolar range whereas their linear counterparts 
had a much weaker affinity65. In another study of Giebel et al., a panning against streptavidin with 
cyclic peptide libraries resulted in the isolation of ligands having on average 100 to 1000-fold better 
binding affinities as compared to linear peptides selected against the same target66.  
A later approach consisted in diversifying the peptide formats using variations in the size of the 
loop and of newly added exocyclic regions37. With this aim, Fairbrother et al. generated phage-
encoded libraries with the format XmCXnCXo (n = 4-10, m+n+o =18) and used them in a screen 
against vascular endothelial growth factor67 (VEGF). Their results showed that a specific peptide 
format is usually preferred for a given target. This underlined the importance of screening multiple 
libraries having different peptide formats in order to increase the chances of isolating binders with 
desired affinity and specificity.  
However, disulfide bridges are susceptible to reduction and disulfide exchange reactions. 
Therefore, other cyclization reactions leading to non-reducible cyclic peptides are desirable. The first 
phage-encoded peptides cyclized in such manner were the so-called bicyclic peptides developed by 
Heinis and Winter in 200968. With their method, they could generate polycyclic compounds by 
Chapter 1 - Introduction 
14 
connecting the three cysteines of a displayed peptide with a trivalent thiol-reactive small molecule. 
Phage display and selection of bicyclic peptides is further described in the section 1.3 of this 
introduction. This pioneering strategy was then followed by many other examples, in which the 
nature and the function of the chemical linker was varied39,69. For instance, several groups have aimed 
at generating photoswitchable cyclic peptides circularized with an azobenzene moiety38,70,71.  
?????? ????????????????????????????????????????????????????????????????
To date, peginesatide is the only cyclic peptide isolated by phage display that has been approved 
by FDA. However, the drug was withdrawn one year after its approval in 2012 due to toxicity issues. 
It consisted of a 45 kDa PEGylated peptide acting as an agonist of erythropoietin and was used for the 
treatment of chronic kidney disorder associated anemia40. Peginesatide was initially isolated from a 
cyclic peptide library having the CX8C format (C = cysteine X = any canonical amino acid) and further 
affinity matured with the generation of two different phage libraries72,73.  
Another three peptides isolated by phage display are currently in clinical trials26. The 
pharmaceutical company Apellis has brought a PEGylated cyclic peptide inhibitor of complement 
factor C3 called APL-2 to the clinic. The molecule is currently undergoing evaluation in phase II for 
age-related macular degeneration (AMD) and is derived from a 27-mer peptide identified during 
phage selections against C3b74. The second one is ALRN-6924, a stapled peptide inhibitor of MDM2 
and MDMX that restores normal p-53 mediated apoptosis activity in malignant cells75. ALRN-6924 
was generated by optimizing the phage selected stapled peptide ATSP-7041. The molecule, developed 
by Aileron therapeutics, has reached a phase I/II clinical trial for the treatment of solid tumors and 
lymphomas.  
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1.3?– Bicyclic peptides 
?????? ??????????????????????????????????????
Inspired by the favorable properties of phage-selected cyclic peptides, Heinis and Winter 
developed a new strategy to evolve bicyclic peptides on phage68 (Figure 6). Their approach was aiming 
at obtaining even more constrained structures that would lead to a better affinity and stability. For 
their cyclization, they utilized an already existing chemistry that was introduced by Timmerman and 
co-workers in order to generate peptides mimicking non-linear epitopes of antibodies46. The idea was 
based on the reaction of a peptide containing three reduced cysteines with the trivalent thiol-reactive 
compound 1,3,5-tris(bromomethyl)benzene (TBMB). When performed in aqueous conditions, the 
reaction was shown to be quantitative, fast and selective for the thiol functional groups of cysteines. 
 
Figure 6. Phage selection of combinatorial bicyclic peptide libraries. Peptides containing three 
cysteines are exposed on pIII at the surface of a fd phage and chemically modified with TBMB. 
Random amino acid loops are encoded on the phage vector and indicated in blue and red. Libraries 
of bicyclic peptides are subjected to two or three rounds of affinity selection against an immobilized 
target. Weak and non binders are washed away and specific ligands are isolated and re-infected into 
E.coli. They can be either re-amplified for another round of panning of sequenced in order to 
identify peptide ligands. 
In a proof of concept work published in 200968, Heinis and Winter showed that this reaction 
was compatible with phage and generated a large combinatorial library of more than 109 peptides 
containing two loops of six random amino acids flanked by three cysteines (format: ACX6CX6CG, 
named 6x6). In order to avoid side reactions with the cysteines of the D1 and D2 domains of pIII, the 
library was fused to the N-terminal end of a genetically-engineered disulfide-free pIII76. Phage 
carrying this mutated version of pIII are about hundred times less infective than the wild type phage 
but tolerate a great variety of alkylation and reduction reactions. After phage production, the cysteines 
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were reduced using TCEP and further modified using TBMB. Three rounds of iterative selections 
against Plasma Kallikrein (PK) yielded bicyclic peptide inhibitors with IC50s in the nanomolar range 
whereas their linear equivalents were nearly 250-fold less potent68. An additional affinity maturation 
selection allowed the identification a potent inhibitor of PK with a dissociation constant in the low 
nanomolar range (PK15; KI = 1.5 nM).  
This phage based strategy has been routinely applied to generate bicyclic peptide ligands to a 
variety of therapeutically relevant targets. As a result, bicyclic peptides with nanomolar affinities and 
good specificity could be identified and further characterized. A large effort has also been invested in 
the generation of combinatorial libraries of bicyclic peptides with higher structural diversity. The 
work done in these directions is discussed in the following subsections. 
?????? ?????????????????????????????????????????????
Combinatorial libraries of peptides with large diversity are particularly interesting for the 
identification of ligands with high affinity for therapeutic targets. Although the randomized regions 
of phage-encoded peptide libraries offer a huge theoretical diversity, the achievable diversity is usually 
limited to 109 – 1010 clones considering the limited number of bacteria that can be transformed with 
DNA plasmid. However, other features of the bicyclic peptides can be modulated such as the number 
of amino acids in each of the two rings and the type of chemical linker used to cyclize the peptide. 
These two strategies induce major structural variations of the molecular backbone and are essential 
for the isolation of peptide ligands making compatible interactions with their targets. Both of them 
have been evaluated in our laboratory and are described in the following paragraphs.  
 As already discussed in the section 1.2.2, the number of amino acids in the loops of a cyclic 
peptide ligands can considerably influence its ability to bind to a specific target. The importance of 
screening multiple libraries of cyclic peptides had already been demonstrated by Fairbrother et al. in 
a work where they used libraries with the format XmCXnCXo67 (C= cysteine and X = any natural amino 
acid; n = 4-10, m+n+o = 18). A selection against VEGF with these libraries revealed that one particular 
format was preferentially enriched during the panning. Similarly, there was a need for phage libraries 
of differently sized bicyclic peptides. This was first illustrated with a problem encountered during the 
development of a plasma kallikrein inhibitor77. The bicyclic peptide PK15, isolated from the 6x6 
library, displayed a good affinity for the human protease (KI = 1.5 nM) but had little or no activity on 
mouse and rat orthologs. As a result, PK15 could not be tested in animal models. This strong 
specificity was attributed to the relatively large loops of 6 amino acids that were likely to interact with 
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regions of PK that are not conserved in the human and murine orthologs. For this reason, libraries of 
shorter macrocycles were tested in phage selections - the library 5x5 or 3x3 that contain two loops of 
5 or 3 amino acids each, respectively. This resulted in the isolation of a clone from the 5x5 library that 
inhibited human, monkey and rat PK with KI values in the low nanomolar range while sparing 
paralogous proteases. These observations motivated the creation of another three different bicyclic 
peptide phage libraries of the format ACXmCXnCG, where m and n can take values from 3 to 678 
(Figure 7). These highly structurally diverse libraries, named A, B and C, were used in a selection 
against Urokinase-type plasminogen activator (uPA) and consensus sequences were found for all of 
the new formats. Although none of the new isolated ligands had a better affinity than the peptide 
UK18 initially identified with the 6x6 library, they revealed new binding motifs that were not found 
with this library.  
 
Figure 7. Phage display libraries of differently sized bicyclic peptides. a) The chemical structure 
of a representative bicyclic peptide (UK368) in green is represented together with peptide rings of 
3, 4, 5 and 6 amino acids for size comparison (in grey) b) The libraries created by Rentero et al. 
combine loops of different lengths. The scheme shows the loop combinations in the library A (dark 
green), B (light green), C (black) and of the former 6x6 library (red). Reprinted with permission 
from78, reprinting license n° 4124710316221, copyright © 2012 Royal Society of Chemistry. 
 In parallel, the use of alternative cyclization linker has also greatly contributed to improve the 
diversity of phage-encoded bicyclic peptide libraries. TBMB, the initial molecule used by Heinis and 
Winter, is a rather small molecule and does not display any H bond donor or acceptor68. Therefore, 
the linker itself can only form hydrophobic interactions with the target or with the amino acids 
present in the peptide loops. Additionally, NMR and crystal structures of two in-vitro evolved bicyclic 
peptides, PK15 and UK18, showed that the mesitylene core did not make any noncovalent bonding 
with the peptide loops68,79. In a study of Chen et al., two other linkers were introduced with the aim of 
conferring new geometries to bicyclic peptides as well as favoring intramolecular H-bonding80. Based 
on TBMB structure, the choice was limited to trivalent thiol-reactive compounds with a threefold 
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rotational symmetry (Figure 8). Two molecules were proposed : 1,3,5-triacryloyl-1,3,5-triazinane 
(TATA) and N,N’,N’’-(benzene-1,3,5-triyl)tris(2-bromoacetamide) (TBAB). The calculation of the 
distance between sulfur atoms by molecular dynamics simulation confirmed that the three linkers 
would offer different loop geometry and flexibility (Figure 8).  
 
Figure 8. Structurally diverse small molecules for the cyclization of phage displayed bicyclic 
peptides. a) previous approaches have not favored interactions between the cyclization core (in 
grey) and the peptidic backbone. The use of small chemical linkers with polar groups would enable 
H-bond interactions with the peptide loops and would serves as nucleating scaffold. b) Structures 
of the three reagents chosen to generate bicyclic peptides (before and after reaction). All of them 
have a threefold rotational symmetry as well as three thiol-reactive groups. Potential H-bond 
donors and acceptors are indicated by red arrows. Computed distance ranges between the sulfur 
atoms of the cyclized peptides are indicated. Reprinted with permission from81, reprinting license 
n° 4124710522727, copyright © 2014 John Wiley and Sons. 
TBMB, TATA and TBAB, were successfully applied to phage selections against uPA using the 
3x3 library81. This led to the identification of specific consensus motifs for each of them and showed 
the possibility to triplicate the diversity of the library. The best binder in this selection was a bicyclic 
peptide cyclized with TATA (KI = 85 nM) whose inhibitory activity was not retained when cyclized 
with either TBAB or TBMB. Finally, the crystal structure of uPA in complex with one of the TBAB-
selected bicyclic peptide showed that the linker itself was able to establish hydrogen bonds with the 
side chains and the backbone of the selected peptide.  
Finally, the structural diversity of bicyclic peptide libraries could further be extended using a 
strategy based on the oxidation of peptides with four cysteines82 (Figure 9). Indeed, the enrichment of 
peptides with a fourth cysteine was observed when phage libraries were subjected to panning without 
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chemical modification. Most probably, unpaired cysteines can form disulfide bridges with cysteines 
of neighboring displayed peptides, thus impairing the interaction of the pIII protein with the F-pili 
and TolA receptor during infection of host bacteria. Chen et al. took profit of this observation and 
screened oxydized phage displayed peptides against uPA. After two rounds of selection, 62% of the 
peptides had a fourth cysteine whereas none were found in the control where peptide were cyclized 
with TBMB. Sequencing results revealed the huge topological diversity offered by this method. The 
fourth cysteine appeared in any of the randomized amino acid positions. In addition, a single peptide 
sequence could lead to three different regioisomers which further expand the variety of conformation 
that can be obtained. 
 
Figure 9. Generation of phage-encoded bicyclic peptides cyclized by two disulfide bridges. a) 
Peptides containing three cysteines in fixed positions and random sequences (red and yellow) are 
displayed on phage. A fourth cysteine can appear in the random sequence. Pairs of cysteines are air 
oxidized to form disulfide bridges and three different regioisomers can be formed. In the lower 
reaction, bicyclic peptides are formed by reacting the three cysteine residues with an alkylating re-
agent, such as TBMB. The single product isomer contains three thioether bonds. b) A large number 
of topologically diverse bicyclic structures can be generated by placing the fourth cysteine in any of 
the randomized positions and by forming disulfide bridges between two pairs of cysteines. Re-
printed with permission from82, copyright © 2013 American Chemical Society. 
Nevertheless, the diversity offered by naïve bicyclic peptide phage libraries is sometimes not 
sufficient to isolate clones with desired properties. As a result, the creation of affinity maturation 
libraries is sometimes required. This involves the use of semi-randomized phage libraries based on 
the sequence of a lead bicyclic peptide isolated during naïve selections. To do so, the important 
residues of the lead peptide are identified using regions where a strong consensus was found or with 
the help of an alanine scan. After that, a new library is cloned in which the less important amino acids 
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are randomized with degenerated primers. The newly designed library is then panned against the 
target in one or two rounds of affinity selection with stringent conditions such as a reduced amount 
of immobilized target. This method has been successfully applied in our lab to increase the affinity of 
two bicyclic peptide inhibitors of PK68 and coagulation factor XIIa83 (FXIIa).  
?????? ?????????????????????????????????????????????
Our laboratory has already identified bicyclic peptide ligands and inhibitors to a wide variety 
of targets including trypsin-like serine proteases68,77,79,83, metalloproteases (unpublished data), sortase 
A84, cancer associated cell receptors85,86 and other intracellular proteins such as β-catenin87 and actin 
(unpublished data). The affinity of the lead compounds identified during phage selections varies from 
the picomolar to the micromolar range and could be further improved by affinity maturation and 
medicinal chemistry (Figure 10).  
 
Figure 10. Affinity of bicyclic peptides isolated against a variety of targets. 
Bicyclic peptide inhibitors of trypsin-like serine proteases have been the most extensively 
characterized. Serine proteases are components of signaling pathways that are tightly regulated and 
whose dysregulation can lead to important pathologies. Yet, targeting disease-related serine proteases 
remains challenging, mostly because of the difficulty to achieve selective binding to their active 
sites,88,89. As already mentioned, bicyclic peptides bind to their targets with high affinity and specificity, 
which makes them a promising molecule format for the development of selective serine proteases 
inhibitors. With such strategy, our laboratory isolated potent inhibitors to the trypsin-like proteases 
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plasma kallikrein (PK)68,77, urokinase-type plasminogen activator (uPA)79 and coagulation factor XIIa 
(FXIIa)83.  
PK is involved in the intrinsic coagulation pathway as well as in the kallikrein-kininogen 
system. As a result dysregulation of PK activity can lead to thrombosis and inflammation and its 
inhibition would be beneficial to several pathologies. The only approved inhibitor of PK is a Kunitz 
domain-based polypeptide of 60 amino acids commercialized under the name of kalbitor (Dyax 
Corporation, now owned by Shire)90. It is indicated in the treatment of a rare inflammatory disease 
called Hereditary Angioedema (HAE). As kalbitor has a short in vivo half-life, it is rather used on 
demand during acute attacks in HAE patients91. For this reason, Dyax corporation/Shire is also 
working on the development of long acting inhibitor of PK92. They developed a monoclonal antibody 
called lanadelumab that is currently in phase III for HAE treatment and can be administered twice 
monthly.  
 
Figure 11. Inhibition of human plasma kallikrein by different bicyclic peptides and NMR 
solution structure of PK15. a) Clones PK2, PK4, PK6, PK13 and PK15 were isolated in phage 
selections using two different libraries. PK15 has an affinity of 1.5 nM as calculated with the enzyme 
inhibition assay. b) The peptide loops of conjugate PK15 are shown in yellow (loop 1) and orange 
(loop 2). The mesitylene core, the three Cys residues and the terminal Ala (N-terminus) and Gly 
(C-terminus) are shown in gray. Reprinted with permission from68, license n° 4124750354452, cop-
yright © 2009 Nature publishing group. 
In 2009, the success of kalbitor inspired Heinis and Winter for the generation of smaller 
bicyclic peptide inhibitor of PK68. In their proof-of-concept study, they used their first generation of 
phage-encoded libraries in a selection against the serine protease and isolated PK15, a potent inhibitor 
with low nanomolar affinity (KI = 1.5 nM) (Figure 11). In addition, the bicyclic peptide inhibitor was 
shown to have no activity on homologous proteases such as thrombin and Factor XIa. However, as 
already introduced in section 1.3.2, this strong specificity also resulted in a poor activity against the 
mouse and the rat orthologs, preventing the possibility to test its activity in vivo. This problem was 
solved with a second generation of bicyclic peptide inhibitors of PK that had smaller loop sizes77. 
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Baeriswyl et al. performed a selection with the libraries 3x3 and 5x5 cyclized with TBMB and 
successfully isolated an inhibitor with high binding affinity to human PK (KI = 0.3 nM) and retained 
activity on orthologous monkey and rat PK (KI = 0.4 and 11 nM respectively).  
 
Figure 12.  Summary of different experiments conducted with the uPA inhibitor UK18. a) 
The affinity of UK18 for a range of homolous trypsin-like protease was measured in an enzyme 
activity assay. b) Crystallization of uPA (grey surface) in complex with UK18 (peptide ribbon in 
blue, mesitylene scaffold in red.) c) Prediction of the consequences of L to D-amino acid 
substitution in UK18 using Φ and Ψ torsion angles of Gly11 and Gly13. i. Crystal structure of uPA 
with bound bicyclic peptide UK18 showed potential steric clashes with surface residues of uPA 
when the two glycine residues were substituted with L-or D-amino acids. ii. Newman projections 
of Gly11 and Gly13 with the Φ and Ψ torsion angles found in the structure. D-amino acid 
substitutions in Gly11 create a clash between the side chain of the amino acid and the carbonyl 
group of Arg10; D-amino acid substitutions of Gly13 were not expected to create steric conflicts. d) 
Pharmacokinetic parameters of UK18-fluorescein and UK18-SA21-fluorescein in mice. Both 
compounds were applied intravenously (200 μL of 50 μM), blood samples were taken at the 
indicated time points, and the concentration of conjugate was measured by ELISA. The indicated 
values are averages of at least two mice. Reprinted with permission from79,93,94, copyright © 2012 
American Chemical Society, & reprinting license n°4124750799695, copyright © 2013 John Wiley 
and Sons. 
The second bicyclic peptide isolated against a serine protease is UK18, an inhibitor of uPA. In 
several studies, this enzyme has been shown to favor tumor growth and metastasis by enhancing the 
degradation of the extracellular matrix and helping cancer cell evasion. Therefore, uPA was seen as a 
potential target for the preventive treatment of metastatic cancers95. UK18 was first identified by 
Angelini et al. in a phage selection with the 6x6 library79. As for PK15, It was active in the nanomolar 
range (KI = 53 nM) and had more than 1000-fold reduced affinity for paralogous proteases (Figure 
12a). In order to better understand the binding mechanism of UK18, the inhibitor was co-crystallized 
with its target (Figure 12b). The results underlined the large contact surface between the peptide and 
the protease and also provided useful information for its affinity maturation (Figure 12c.i). 
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Specifically, the analysis of the binding mechanism pointed two glycine residues that could potentially 
be replaced with D-amino acids93 (Figure 12c.i and ii). These two positions were screened for a range 
of natural and non-natural D amino acids among whom two led to improvements of the peptide 
affinity and stability. UK18 has also been particularly important for understanding of the in vivo 
behavior of bicyclic peptides. A pharmacokinetic study showed that the peptide was undergoing rapid 
renal clearance (half-life = 30 min) after i.v injection in mice94 (Figure 12d). After that, two strategies 
were evaluated to increase the circulation half-life: recombinant fusion to a Fc region20 and 
conjugation to an albumin-binding peptide94 (SA21, developed by Dennis and coworkers). These two 
strategies successfully prolonged the blood residence time to 36h and 24h, respectively (Figure 12d). 
Moreover, another mouse study demonstrated that the SA21-conjugate could efficiently diffuse into 
organ tissues and solid tumors96.  
The third example is a bicyclic peptide inhibitor of FXIIa that proved to be very potent both in 
vitro and in vivo. The protease target is the first serine protease of the intrinsic coagulation pathway 
and is also involved in other enzymatic cascades associated with inflammation and immune 
reaction97. As a consequence, FXIIa plays a role in coagulation and/or inflammation related 
pathologies by inducing unwanted blood clot formation98,99. For example, FXIIa dysregulation was 
associated with diseases such as thrombosis or hereditary angioedema (HAE). Moreover, the enzyme 
can also get activated during surgeries in which the blood comes in contact with medical devices, 
leading to life-threatening consequences. This is the case for coronary pulmonary bypass (CPB) and 
extracorporeal membrane oxygenation (ECMO), two medical procedures in which an instrument 
takes over the function of the heart and lungs. Currently, the addition of heparin to the blood 
circulation is the preferred solution to this problem despite strong side effects such as excessive 
bleeding100. For these reasons, the development of bicyclic peptide inhibitor of FXII was regarded as 
an interesting approach to generate safer anticoagulants. Up to now, Dyax101,102 as well as several other 
laboratories103,104 have developed mAbs blocking the activity of FXIIa.  
Bicyclic peptide inhibitors of FXIIa have also been evolved by phage display. A first selection 
performed with the 4x4 library, in which the peptides were cyclized with TBMB, yielded only 
inhibitors with weak affinity (KI ≥ 1.2 μM)105. In a second trial, the structural diversity was increased 
by using several libraries (3x3, 4x4 and 6x6) as well as another linker (TATA)83. As a result, peptides 
with affinities in the nanomolar range were identified and an affinity maturation step enabled the 
isolation of peptide FXII618 with a KI value of 22 nM (Figure 13a). This inhibitor was highly selective 
for FXIIa as compared to the already existing FXIIa corn trypsin inhibitor (CTI) (Figure 13b). It also 
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showed better prolongation of activated partial thromboplastin time (aPTT) which measures the time 
to coagulation upon initiation of coagulation via the intrinsic pathway (Figure 13c). 
 
Figure 13. Comparison of FXII618 and CTI. a) Chemical structure of FXII618. b) Specificity 
profile and inhibitory activity of CTI (upper panel) and FXII618 (lower panel). The residual activity 
of several trypsin-like serine proteases is shown. c) Comparison of activated partial thromboplastin 
time (aPTT) in citrated platelet poor plasma in the presence of the same quantities of FXII618 and 
CTI. Reprinted with permission from83, Copyright © 2015 American Chemical Society. 
Later, the suboptimal affinity and plasma stability of FXII618 was again improved by 
generating small combinatorial libraries (10 to 100 compounds) of peptides by SPPS. In a first 
approach, residues important for stability and affinity were substituted with natural and non-natural 
analogues106. In a second approach, atoms were inserted into the peptide backbone using β-amino 
acids and cysteine analogues107. The amino acid sequence of best mutants were combined together 
and resulted into a 380 pM inhibitor, called JSM33-R that was stable for more than 100h in human 
plasma (unpublished data). In addition, the peptide had an enhanced activity on the mouse ortholog 
(KI = 500 pM). Although JSM33-R has a really short in vivo half-life, it efficiently prevented blood 
coagulation in mouse models in which blood clotting is induced with ferric chloride (unpublished 
data). 
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1.4?– Next generation sequencing (NGS) and phage display 
?????? ??????????????? ????????????????????
In most cases, the analysis of phage panning outputs is done by Sanger sequencing. However, 
NGS has recently gained increasing attention from research groups performing phage selections. This 
technology has revolutionized the field of genomics and DNA sequencing by providing exceptional 
volumes of sequence data at an unprecedented speed and low cost108. In 2008, Mannocci et al. applied 
NGS for the first time to DNA-encoded libraries for the in vitro evolution of ligands109. Using 454 
pyrosequencing110, they successfully identified binders to streptavidin pulled out from a library of 
4000 different compounds. After them many laboratories have worked with NGS to analyze naïve or 
matured phage libraries of peptides111–113, antibodies114–116 or protein domains117–119. In the majority of 
the cases, results were obtained with technologies110 such as Illumina platform115,116, 454 sequencing 
technology114,117,118 or ion semiconductor sequencing111,119 (Figure 14). In all these methods, the phage 
vector DNA is isolated by extracting plasmid dsDNA from infected E.coli. In a second step, the 
fragments of interest are amplified by one or two PCR resulting in amplicons flanked with adaptor 
sequences compatible with consecutive NGS (Figure 15).  
 
Figure 14. Specificities of different NGS technologies in terms of read length and throughput. 
Points represent official platform/chemistry combination releases and are color-coded based on the 
platform family. Reprinted (open access) from110, this article is available under the terms of CC-BY 
3.0 license. 
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Figure 15. General procedure for NGS of phage-encoded polypeptides. (1) In the biopanning 
phase, the phage-encoded library is incubated together with the immobilized target. After washing 
away nonbound phages, binders are isolated and amplified in bacteria. The amplified libraries can 
be reused in a subsequent round of biopanning. (2) Alternatively, the DNA of the phages can be 
isolated usually after the propagation step (3) and amplified with PCR primers complementary to 
sequences flanking the region of interest. The PCR primers contain tails with the adapter sequences 
necessary for NGS. This step can involve more than one PCR (4) DNA fragments are purified (5) 
and sequenced (in this scheme, with Illumina technology). (6) Finally, the data are analyzed using 
bioinformatics tools. Adapted from, reprinting license n°4124760047073, copyright © 2012 
Elsevier Ltd. 
The first NGS of phage selected ligands was performed by Dias Nesto et al. using 454 
pyrosequencing108. They obtained around 50 000 reads and analyzed them with the aim of identifying 
peptides selected against different organs. The same technology was applied in other phage panning 
and has been especially useful for the sequencing of antibody repertoires due to the long size of the 
reads (up to 700 bp)114 (Figure 14). Nowadays, methods providing higher throughput are the most 
popular. In particular, Illumina platform is the most widely used because it can generate up to 4 billion 
different reads with low error rate as compared to 454 pyrosequencing and ion semiconductor 
sequencing110. However, the shorter read length has impaired the sequencing of entire single chain 
variable fragments (scFv) (Figure 14). As a result, NGS of antibody libraries has for a long time been 
restricted to the analysis of complementarity-determining region 3 (CDR3)119,116. Indeed, these 
domains were demonstrated to be the most relevant contributors to antibody specificity and are 
sometimes the only randomized regions in scFv libraries116. Last year, Lövgren et al. overcame for the 
first time these limitations and sequenced all the CDR of a framework antibody repertoire with 
Illumina technology115. This was achieved with the recently developed Illumina V3 2x300 bp paired 
end sequencing. As a result, they could easily replicate the enriched scFv by means of DNA synthesis, 
cloning and recombinant expression. Finally, another breakthrough in the analysis of phage selection 
data by NGS has been the use of barcoded primers for the preparation and multiplexing of the 
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sequenced DNA libraries. Sidhu and co-workers pioneered this approach and were able to analyze 22 
independent panning experiments in a single run117.  
The application of NGS to phage displayed peptides provided valuable information about the 
diversity and abundance of selected clones and helped monitoring enrichment during the selection 
and amplification procedures. In most cases, peptides are ranked according to their copy number and 
the most frequent clones are further synthesized and characterized115,119. However, in some selections 
the average abundance is low and the isolated peptides diverse, which makes the identification of 
relevant clones difficult. As a consequence, other approaches based on sequence homology were 
developed113,120. For example, clustering of several thousands of peptides allowed the determination 
of target-specific consensus sequences and enabled to discriminate clones selected against M2 
macrophages from the background121. NGS has also enhanced the recognition of target-unrelated 
peptides (TUPs). Indeed, there are several reasons that explain unintended selection of TUPs in phage 
pannings112,122,123. First of all, proliferation advantages during the phage amplification steps can have a 
profound impact on the output of the selection. Second, peptides can be systematically isolated 
because of their affinity to constant parts of the screening platform such as plastic or beads. One way 
to avoid the enrichment of TUPs is to reduce the number of iterative rounds of panning as illustrated 
with the work of ‘t Hoen et al 112. Other procedures consist of including several biological replicates as 
well as an unselected but amplified library120,121,123. Actual target binders should appear with similar 
frequency in both replicates but should be much less abundant or absent in the negative control.  
?????? ??????????????????????????????????????????????????????
In the past, our laboratory was working with Sanger sequencing, resulting in labor and cost-
intensive procedures that were rarely used to analyze more than a hundred clones per selection. 
Members of the laboratory speculated that NGS would help to identify target-specific binding motifs 
and afford a better coverage of all the diversity of isolated peptides. In line with this objective, Rentero 
et al. developed a method based on Ion Torrent PGMTM platform given the high throughput (106 to 
107 reads) and adequate read length (approximately 200 bp length on the Ion 316TM Chips they used) 
offered by this technology. For their experiment, they isolated plasmid DNA from phage infected 
bacteria and amplified the region of interest by PCR. During this step, a six-letter barcode was inserted 
via the forward primer, allowing the multiplexing and sequencing of several phage selections in a 
single run. After production of the DNA libraries, samples were run on an Ion316TM Chip yielding a 
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total of more than 106 sequences that could be separated into different files according to their 
barcode120.  
Consecutively, Rentero et al. developed a tool to analyze NGS data of phage selected peptides 
based on both abundance and sequence homology. The different scripts were written with the 
MATLAB software and were used to (i) filter reads with suboptimal quality, (ii) eliminate erroneous 
clones appearing during sequencing or PCR, (iii) classify peptides according to the number of cysteine 
residues and ring size, (iv) order peptides into consensus sequences and finally compare different 
datasets with each other (Figure 16).  
 
Figure 16. NGS and sequence analysis strategy of Rentero et al. (A) Primer design for Ion 
Torrent sequencing of bicyclic peptide libraries. The insertion of barcodes enable the multiplexing 
of several phage selection outputs on the same chip (B) Procedure for the analysis of sequencing 
data applying MatLab scripts. First, reads are separated into several files according to their 
barcode/selection. Second, low-quality sequences are removed from the dataset, and remaining 
sequences are translated and sorted by abundance. Additionally, peptides can be distributed based 
on their format (e.g. peptide ring size in the case of bicyclic peptides) and datasets compared with 
each other. Then, the sequences of the most abundant peptides (e.g. top 200) are compared and 
clustered in consensus groups, allowing the identification of specific motifs. Finally, the entire pool 
of sequences is searched for other less abundant sequences sharing such motifs in order to identify 
promising candidates. Reprinted (open access) from111, this article is available under the terms of 
CC-BY 4.0 license. 
Filtering sequences with substandard quality was a critical step in the data processing. Indeed, 
all sequencing technologies including ion semiconductor sequencing can lead to insertion/deletion 
errors that are often caused by inacurate flow calls occuring during the sequencing of homopolymeric 
regions. In order to detect these events, sequencing data are provided with Q-values, which indicate 
the confidence of each scanned nucleotide. Q-values are indicated with a single-character Phred-
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based quality score. Rentero et al used this information to develop a function in which reads 
containing low confidence basecalls can be removed. Practically, the filter excludes all sequences with 
more than x (X ≥ 1) bases having a quality score below a certain value, often chosen as Q18. Both 
parameters can be modulated according to the need of the user. The remaining sequences are 
translated and sorted by abundance.  
In a second script, reads arising from sequencing or PCR errors could be eliminated. These 
reads overrule the quality filtering and are still easily spotted because they have identical nucleotide 
sequences except for one or two positions (Figure 17). Indeed, with the size and the diversity of our 
standard libraries, the probability to have two clones with almost the exact same nucleotide sequence 
is close to zero. Peptides present in high copy number will engender more sequencing errors that can 
be misleading and result in the generation of incorrect consensus group. The fixingerrors.m function 
enables one to pool together all DNA sequences differing only by a specified number of bases 
determined by the user (Figure 17). The procedure is iterative and time consuming when large data 
set are analyzed. For this reason, the number of sequences to correct can also be selected and the most 
abundant clones are processed first.  
 
Figure 17. Example for the identification of false consensus sequences due to sequencing 
errors. In this selection, the most abundant sequence (present 4592 times) was clustered with 
sequences differing in only 1 nucleotide and being present at much lower frequency. These 
sequences likely resulted from sequencing errors. The fixingerrors.m function fount 467 erroneous 
reads arising from this parental sequence. Reprinted (open access) from111, this article is available 
under the terms of CC-BY 4.0 license. 
The number of cysteines found in phage-selected bicyclic peptides can often indicate how they 
have been cyclized. For example, oxidized peptides often are selected with four cysteines. In addition, 
some formats are preferentially enriched when performing panning with pooled libraries containing 
different ring sizes. As a result, a script was written in order to be able to classify and separate peptides 
according to these parameters. This allows the identification of peptide topologies favored during 
selections against specific targets.  
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One of the most important achievements was the creation of a function allowing the clustering 
of peptides into consensus groups. The script is based on the calculation of pair-wise distances 
between peptides. Subsequently, it generates a phylogenetic tree and finally organizes clones 
according to particular sequence motifs. Several parameters can be varied by the user such as the 
number of sequences to cluster, the stringency, the minimal size of a cluster etc. However, the number 
of clones that can be analyzed for similarity is usually inferior to 1000 due to the long processing time. 
Finally, the CommonSeq.m function allows the comparison of two to three data set with each 
other. This was used to compare two parallel independent selections against the same target and 
facilitated the identification of target binding motifs from noisy dataset. 
Since its development, NGS of phage-selected bicyclic peptides has been particularly valuable 
for the identification of rare target binding peptide motifs and choose appropriate peptide leads. This 
has been the case for selections against β-catenin87, sortase A84 and other unpublished projects. 
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2. Aim of the thesis 
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The goal of my thesis was to develop new methods for the phage display selection of (bi)cyclic 
peptides. Specifically, I aimed at the following three objectives: (i) increasing the scaffold diversity of 
phage-encoded bicyclic peptide libraries by cyclizing peptides with two chemical bridges, (ii) selecting 
peptide macrocycle ligands using phage libraries with unprecedented small size and (iii) bypassing 
bacterial infection in phage display by sequencing DNA released from phage particles.  These three 
aims are described in details in the following paragraphs. 
(i) Small structural diversity is a major limitation of combinatorial peptide macrocycle 
libraries. This problem can result in the isolation of peptides with suboptimal affinity, specificity, 
and/or stability. In most cases, our laboratory has successfully solved these problems by varying the 
backbone of the macrocycle. This has been achieved by cloning libraries with different ring size78 as 
well as by using different chemical linkers81. At the beginning of my PhD, our laboratory was in 
possession of seven different libraries of bicyclic peptides, each of them having different combinations 
of ring sizes. In addition, two commercially available trivalent linkers – TBMB and TATA – could be 
employed to cyclize phage exposed peptides. All together, these libraries and linkers could be applied 
to generate phage-encoded libraries of bicyclic peptides containing around 40 different peptide 
backbones. We hypothesized that a much larger scaffold diversity would enable the identification of 
ligands with improved binding properties. Consequently, the first aim of my PhD was to address this 
problem by developing a new strategy that provides rapid access to thousands of different bicyclic 
peptide formats. Together with Dr S. Kale, we established a method in which linear peptides 
containing four cysteines were easily cyclized with two bivalent linkers. As a result, an enormous 
scaffold diversity could be obtained because the two bridges divide a peptide into three segments that 
all can be varied in length in a combinatorial fashion. In addition, the cyclization of peptides with four 
cysteines leads to three regioisomers which would triplicate the diversity. Finally, at least 20 
symmetrical bivalent linkers, having two potential thiol-reactive groups, are commercially available. 
Following this strategy, I performed phage display against plasma kallikrein using libraries cyclized 
with six of the structurally diverse linkers, tested and validated by Dr. Kale. 
(ii) The development of peptide therapeutics that are orally available has been a long standing 
goal in the pharmaceutical industry. Most cyclic peptides are not orally available because they are too 
large and/or polar to passively diffuse through cell membranes. Among all factors influencing cyclic 
peptide passive permeability, the molecular size and the number of H bond donors (HBD) are the 
most important. Peptides with small molecular mass (500 < MW < 1300) and fewer HBD are more 
likely orally absorbed124.  Nevertheless, developing cyclic peptide ligands having a small size is 
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challenging as they have fewer amino acids that can potentially interact with the target. In addition, 
generating large combinatorial libraries of small cyclic peptides is difficult, because cyclization 
strategies often require bridges between two amino acid side chains (e.g two cysteines) which signifies 
that not all amino acids are free for diversification. In this project, my aim was to develop a strategy 
allowing the creation of large phage-encoded libraries of small cyclic peptides that promises intestinal 
absorption. Large combinatorial diversity was achieved using a newly established cyclization reaction 
occurring between the side chain of a C-terminal cysteine and the N-terminal amino group. Unlike 
other cyclization strategies, this method maximizes the ratio between the number of target-interacting 
amino acid side chains and the total number of residues. In order to validate this approach, phage-
encoded libraries of the format XXXC and XXXXC were cyclized with eight structurally different 
linkers and subjected to affinity selection against the two disease targets plasma kallikrein and 
coagulation factor XIa. 
 (iii) In a third project, I intended to verify which fraction of phage clones could be decoded by 
directly sequencing DNA from phage particles isolated after panning. This was motivated by the fact 
that the identification of phage-selected clones invariably requires re-infection into competent E.coli 
before extraction and sequencing of plasmid dsDNA. This can lead to three major complications. 
First, some phage selection procedures depend on phage with mutated coat protein that can lead to 
the generation of poorly infective virions. Second, this restricts the type of post-translational chemical 
modifications that can be applied to phage. Finally, re-infection can create a bias for certain peptide 
sequences and affect the read out of the sequencing results. The two first points are particularly 
important in our laboratory since we are reacting a broad range of chemical linkers with peptides 
displayed on mutated pIII coat proteins of phage and we often observe an impact on phage infectivity. 
Therefore, I tested a new strategy for bypassing this bacterial infection step via direct sequencing of 
the ssDNA contained in phage particles. In this work, high-throughput sequencing was used to 
quantify the fraction of phage clones that could be identified using this approach.  
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3. Cyclization of peptides with two 
chemical bridges affords large scaffold 
diversities 
?
This chapter is based on a manuscript that has been submitted for publication 
and is currently under review.  
This work has been done in collaboration with Dr Sangram Kale. S. Kale and I 
will be shared first authors for this publication. Results produced by S. Kale are 
marked. Author contribution: S. Kale, Prof. Heinis and I conceived the strategy, 
designed experiments and analyzed data. S. Kale established the chemical 
reactions. I tested the impact of linkers on phage infectivity. I performed the 
phage selections and next generation sequencing. S. Kale and I synthesized 
purified and characterized the peptides. 
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3.1 – Abstract 
Successful screening campaigns depend on large and structurally diverse collections of 
compounds. In macrocycle screening, variation of the molecular scaffold is important for structural 
diversity, but to date it is challenging to diversify this aspect in large combinatorial libraries. Herein, 
we report the cyclization of peptides with two chemical bridges to provide rapid access to thousands 
of different macrocyclic scaffolds in libraries that are easy to synthesize, screen, and decode. 
Application of this strategy to phage-encoded libraries allowed for the screening of an unprecedented 
structural diversity of macrocycles against plasma kallikrein, important in the swelling disorder 
hereditary angioedema. These libraries yielded inhibitors with remarkable binding properties (sub-
nM Ki, > 1,000-fold selectivity) despite the small molecular mass (~ 1200 Da). An interlaced bridge 
format characteristic of this strategy provided a high proteolytic stability (t1/2 in plasma > 3 days), 
making double-bridged peptides potentially amenable to topical or oral delivery. 
3.2 – Introduction 
Macrocycles have emerged as an interesting therapeutic class because they can bind to 
challenging targets that are not easily accessible to traditional small molecule compounds4,125. They 
owe their favorable binding properties to a larger size that enables interactions with extended surfaces 
where small molecules cannot normally bind and a ring-shaped structure that limits the 
conformational flexibility, and thus the entropic penalty, upon target binding126. The vast majority of 
macrocycle drugs are natural products or derivatives thereof127. For many targets, there are no 
available natural product-derived macrocycles, or the high complexity of the natural product hampers 
their synthetic modification and optimization. Thus, there is a need for synthetic macrocycles that are 
developed in a combinatorial fashion, which can greatly reduce the overall complexity. The necessary 
library diversity required to make these combinatorial macrocycles can be acquired by incorporating 
variable backbone structures (macrocyclic scaffold), by decorating the scaffolds with diverse 
functional groups, and by attaching peripheral substituents outside of the main ring. The variation of 
the macrocyclic scaffold is considered to be the most important determinant of structural diversity128. 
Therefore, a key step for achieving a high structural diversity in combinatorial macrocyclic libraries 
is to find a way to incorporate these variable scaffolds into the screening system. To this end, a range 
of elegant diversity-oriented synthesis strategies were published in recent years129. However, the 
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development of strategies for diversifying the scaffolds in large combinatorial libraries comprising 
ideally millions of macrocycles remains an important challenge. 
Display technologies such as phage and mRNA display have enabled the generation and 
screening of enormously large numbers of peptide macrocycles, typically reaching several billion 
compounds at a time48,35,130,131. Efficient chemical reactions allow for the transformation of genetically 
encoded linear peptides into cyclic structures, which can provide access to variably cyclized peptides 
while retaining the benefits of the genetically encoded library45,132. Typically, two or three amino acids 
are ligated to generate mono- or bicyclic peptide libraries. By combining orthogonal reactions, more 
complex macrocycle structures have also been generated. Recent technology innovations have 
enabled the incorporation of unnatural amino acids into mRNA display, expanding the diversity of 
chemical groups that can be used to build these types of libraries133. To this point, however, a major 
limitation of phage or mRNA display macrocyclic libraries is the low scaffold diversity. Due to the 
dependence on ribosomal translation, the backbones of the macrocycles are required to be 
polypeptidic in nature. In most of the reported libraries, the macrocycles contain a single polypeptide 
scaffold, and the diversity is based only on the variation of the amino acid side chains. By varying the 
number of amino acids in the random peptides53,78,134 or the chemical cyclization linkers81, libraries 
comprising several different scaffolds were generated, but none of the reported libraries contains 
more than a dozen different scaffolds. 
Here we report an efficient and robust strategy for generating phage-encoded macrocyclic 
libraries that contain thousands of different scaffolds. We cyclize peptides through two chemical 
bridges that connect two pairs of cysteines (Figure 18a). The two bridges subdivide the peptides into 
three segments containing m, n and o random amino acids, respectively (highlighted in red, orange 
and green in Figure 18a). Altering the number of random amino acids in each segment in a 
combinatorial fashion allows for the generation of a much larger scaffold diversity than when peptides 
are divided by only two or three cysteines into one or two segments, respectively. Additional structural 
diversity stems from the connectivity between the cysteines, due to the fact that four cysteines can be 
connected by two chemical linkers three different ways. The greater number of different bicyclic 
peptide scaffolds that can be generated with two chemical bridges as opposed to only one is 
exemplified for example 9-amino acid peptides in Figure 18b. While cyclizing nonapeptides with one 
bridge (3 cysteines, 6 random amino acids) yields only 7 different bicyclic scaffolds, two bridges (4 
cysteines, 5 random amino acids) yields 63 different bicyclic scaffolds. This already provides a nine-
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fold improvement in diversity that will increase with an increasing peptide size. For peptide 
macrocycles between 8 and 14 amino acids in length (including the four cysteines), a total of 798 
different di-bridged bicyclic peptide formats can be obtained versus the 63 that are possible with a 
mono-bridge connecting three cysteines. The scaffold diversity can be further increased by cyclizing 
the same peptide library in parallel with many different chemical bridges that can further vary the ring 
size as well as include functional groups that can participate in binding. Dozens of reagents with two 
thiol-reactive groups are commercially available135, in direct contrast to the only two commercially 
available reagents with three symmetrical thiol-reactive groups81. This calculation based on the 
cyclization of 8- to 14-mer peptides with 10 different bridges has the potential to yield  > 7000 different 
macrocyclic scaffolds. 
 
Figure 18. Cyclization of peptides with two chemical bridges. a) Cyclization of peptides with 
two chemical bridges (connecting four cysteines) yields a much larger number of bicyclic peptide 
scaffolds than cyclization with one bridge (connecting three cysteines). The number of different 
macrocycle scaffolds is indicated for peptides of different lengths. b) Illustration of the large 
macrocycle diversity with a double-bridged nonapeptide as an example. 
An important goal of our laboratory is the development of small, highly stable peptide 
macrocycles that can be applied topically or orally. Developing such small and compact ligands can 
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be challenging because they have fewer amino acids that can interact with targets. We speculated that 
this handicap may be overcome by a molecular shape that is perfectly complementary to a target 
binding site, and that such molecules could potentially be isolated from macrocycle libraries with high 
scaffold diversities. We thus applied the “double-bridge” cyclization strategy to small-sized peptides 
and used these to isolate inhibitors of plasma kallikrein. This protein is an important target of the 
swelling disorder hereditary angionedema to which injectable, protein-based inhibitors are already in 
clinical use136,137 or development138 but no small molecule drug is currently available. 
3.2?– Results 
?????? ???????????????????????????????????????
 
Figure 19. Cyclization reagents and reaction efficiency. a) Chemical linkers each containing two 
thiol-reactive groups. b) Reaction of the model peptide ACSRCVECGWCG-NH2 with the 
indicated concentrations of chemical linker 3. Products were analyzed by analytical HPLC. At all 
reagent concentrations, the major products were the three desired double-bridged peptides. c) 
Products formed upon incubation of the model peptide with twelve different chemical reagents at 
the indicated concentrations. Fields shaded with dark gray indicate that the major product was the 
double-bridged peptide (sum of three isomers > 50% of total product). Minor products are 
indicated with small letters: a. bicyclic peptide, b. non-bridged modification, c. single bridge, d. not 
identified. – Data produced by Dr S. Kale 
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A number of reagents containing thiol-reactive groups were reported to efficiently cross-link 
or cyclize peptides and proteins via cysteines in aqueous buffer and under mild conditions139–142. Of 
those, we chose 12 structurally diverse compounds and tested their ability to quantitatively and 
selectively link two pairs of cysteines in a model peptide in conditions that are compatible with phage 
display (ACSRCVECGWCG-NH2; Figure 19a). Eight out of the 12 reagents produced the double-
bridged peptide as the main product at a wide range of concentrations, suggesting that the reactions 
are robust and would work efficiently with peptides of variable sequences when displayed on phage 
(Figure. 19b and c). The observed side products were mostly peptides with only one bridge and, at 
higher reagent concentrations, peptides that were modified with more than two linkers such that the 
cysteines were not bridged.  
?????? ????????????????????????????????????????????????????
 
Figure 20. Influence of chemical modification on phage infectivity. 1011 t.u. of phage from li-
brary 1 were incubated with different concentrations of the linkers in 80% aqueous buffer (20 mM 
NH4HCO3, pH 8) and 20% ACN for 1 h and the number of infective phages was determined. 
Most of the thiol-reactive compounds did not inactivate filamentous phage or only interfered 
at concentrations far above those needed to fully cyclize the model peptide (Figure 20). 
?????? ????????????????? ????????????????????????????????
We applied the compounds 1, 3, 4, 7, 10 and 12 to two peptide phage display libraries each 
comprising more than 100 million random peptides of the formats XCX3CX3CX-phage (library 1) 
and XCX4CX4CX-phage (library 2). In these libraries, there was a 20% and 23% chance, respectively, 
for the peptides to contain four cysteines due to the probability of a cysteine occurring in the random  
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Figure 21. Phage selection of double-bridged peptides. a) Abundance of peptide formats after 
two rounds of panning library 1 cyclized with the indicated linkers against plasma kallikrein. 
Abundance is indicated in % of those peptides containing four cysteines. Abundance of peptide 
formats enriched from library 2 is shown in Supplementary Figure 3.2. b) Peptides isolated from 
libraries 1 and 2 after two rounds of panning using linkers 3 and 10. Peptides with similar sequences 
are aligned in groups and amino acid similarities highlighted in color. Peptide formats isolated with 
four other linkers are shown in Supplementary Figure 3.3.Ten peptides were synthesized and 
characterized. The KI of the most active isomer of each peptide is indicated. Standard deviations of 
at least three KI measurements are shown. 
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positions. Cyclization of the peptides yielded 54 different backbone formats for each linker 
(Supplementary Figure 3.1), producing 324 different macrocyclic scaffolds in total. The two libraries 
each cyclized with the six different linkers were individually panned against immobilized plasma 
kallikrein. High-throughput sequencing of phage isolated after two rounds of selection showed an 
enrichment for peptides containing four cysteines, that the fourth cysteine was localized to certain 
positions depending on the thiol-reactive reagent used (Figure 21a for library 1; Supplementary 
Figure 3.2 for library 2), and that peptides shared strong consensus sequences (Figure 21b and 
Supplementary Figure 3.3). These findings suggested that the library peptides were efficiently cyclized 
on phage, due to the strong prevalence of four cysteines, and that target-selective peptides were 
isolated because of the consensus. In phage selections with linkers 3 and 10, certain peptide formats 
were particularly enriched (Figure 21b). For example, most peptides cyclized with linker 3 contained 
the fourth cysteine in amino acid position 3. In the selection with linker 10, many of the peptides 
isolated had the truncated format XCX2CCX2CX, which contained 10 instead of 11 amino acids. Such 
truncated peptides are generated during library cloning through erroneous DNA primers and occur 
only rarely in the finished library. The strong enrichment of some peptide formats, especially such 
rare formats, suggested that certain molecular scaffolds are particularly suited for target binding. This 
finding was the first hint that the high scaffold diversity obtained through the double-bridge strategy 
was key for the isolation of binders. 
?????? ???????????????????????????????????????????????
We synthesized several peptides and cyclized them by randomly bridging two pairs of cysteines 
through all three possible combinations, and each isomer was separately isolated and tested for 
binding. We picked the short peptides of 10 or 11 amino acids isolated from library 1 cyclized with 
linkers 3 and 10 due to our interest in small macrocycles (~1200 Da). The KIs of the most active isomer 
for each peptide are indicated in Figure 21.b. Most of the peptides had activities in the nanomolar 
range, with some reaching sub-nanomolar KIs. For each peptide, there was obviously one isomer that 
was the selected format, as one of the three tested isomers proved to be the best inhibitor for plasma 
kallikrein. Because it was so important for the activity, the connectivity of two peptides, PK4 and PK6, 
was deciphered by synthesizing the three isomers using orthogonal cysteine protecting groups Mmt 
and Dpm (Supplementary Figure 3.4 and 3.5). An efficient procedure including one on-resin 
cyclization was established that enabled the synthesis of double-bridged peptides in two days. It was 
determined that for PK4, isomer 3 (Cys1/Cys3, Cys2/Cys4) inhibited the protease with a KI of 0.7 ± 
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0.1 nM while the other two isomers showed at least a 200-fold weaker inhibition (Figure 22a). In PK6, 
isomer 1 (Cys1/Cys2, Cys3/Cys4) was by far the most active (KI = 3.2 ± 0.5 nM) (Figure 22a). Not 
surprisingly, the most active inhibitors of a consensus group had the same cysteine connectivity and 
thus the same macrocyclic scaffold. 
 
Figure 22. Role of chemical bridges. a) Structures of the three isomers of PK4 and PK6. One out 
of the three isomers efficiently inhibits plasma kallikrein. HPLC traces of the active isomers are 
shown in Supplementary Figure 3.5. b) Replacement of the chemical bridges in PK4 and PK6 
reduced the inhibitory activity to various extents. c) SAR study of PK2 (isomer 3). Inhibition of 
plasma kallikrein and FXIa by PK2 variants with the indicated amino acid substitutions. – Data 
shown in b and c were produced by Dr S. Kale.  
?????? ?????????????????????????????????????????????????????????
The convergence of peptides to certain consensus groups based on the use of different linkers 
indicated an important structural and functional role for the chemical bridges. We assessed the role 
of the two linkers in the double-bridged peptides PK4 (isomer 3) and PK6 (isomer 1) in a structure-
activity relationship (SAR) study in which we replaced one linker at a time to a set of diverse linkers 
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(Figure 22b, Supplementary Figures 3.6, to 3.8), some of which rendered the peptide macrocycles 
entirely inactive at the highest concentration tested (1 ?M). This linker swapping experiment showed 
that both of the two bridges are important. We then wondered if linker substitution could be a strategy 
for enhancing the macrocycles’ inhibitory activities. To test this, we substituted linker 3 in the most 
active macrocycle PK2 (isomer 3; KI = 0.5 ? 0.1 nM) with para-dibromomethyl-benzene linkers 13-
19 carrying diverse groups attached to the benzyl ring (Figure 23). While none of the macrocycles had 
an enhanced activity, we discovered that some of them again had a dramatically reduced activity, 
showing that even minor structural changes in the linker, such as the addition of small substituents, 
substantially impact the macrocycle activity. This suggested that linkers 13-19, despite the similarity 
to 3, should all be applied in parallel in future phage selections in order to generate even larger 
diversities. 
 
Figure 23. Cyclization of peptides with linkers having similar structures. a) Chemical reagents 
resembling linker 3. b) Inhibition of plasma kallikrein by bicyclic peptide PK2 (isomer 3) in which 
one of the two linkers was substituted.  
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?????? ????????????????????????????????????????
The macrocycles PK2, PK4, and PK6 showed high target selectivity in a specificity profile 
performed with a panel of eight homologous trypsin-like serine proteases (Table II). Six of the 
proteases were not inhibited at all. Even coagulation factor XIa (FXIa), sharing the highest sequence 
identity with plasma kallikrein (69% amino acid homology in the catalytic domain), was only weakly 
inhibited, and the macrocycles still demonstrated around 1000-fold selectivity for plasma kallikrein 
over FXIa. We subsequently investigated the structural determinants of the target specificity for one 
of the macrocycles, PK2. Specifically, we tested if PK2 could be turned into a FXIa inhibitor by 
mutating different amino acids (Figure 22c), but none of the substitutions improved the inhibition of 
FXIa. Detrimental mutations reduced the inhibition of both proteases to similar extents, indicating 
that the macrocycle binds both proteases through similar key contacts. Apparently, the backbone 
formed by a XCCX2CX3CX peptide double-bridged by linker 3 fits perfectly to the active site of plasma 
kallikrein and contributes to the target selectivity. 
? KI (nM) 
 PK2 PK4 PK6 PK10 
plasma kallikrein 0.5 ± 0.1 0.7 ±0.1 3.2 ± 0.5 3.6 ± 0.5 
factor XIa 580 ± 180 1300 ± 500 2700 ± 200 2500 ± 100 
factor XIIa > 30000 > 30000 > 30000 > 30000 
thrombin > 30000 > 30000 > 30000 > 30000 
uPA > 30000 > 30000 > 30000 > 30000 
tPA > 30000 > 30000 > 30000 > 30000 
plasmin > 30000 > 30000 > 30000 > 30000 
factor Xa > 30000 > 30000 > 30000 > 30000 
factor VIIa > 30000 > 30000 > 30000 > 30000 
Table II. Target specificity. Inhibition of plasma kallikrein and a panel of structurally 
homologous or physiologically important paralogous proteases by isolated inhibitors. 
Average values and standard deviations of at least three measurements are indicated. – Data 
produced by Dr S.Kale. 
?????? ????????????????????????????????????????????????????
Short peptides constrained by two linkers promised a high proteolytic stability due to the 
inaccessibility of the peptide backbone to proteases. Indeed, some of the double-bridged peptides, like 
PK2 (isomer 3), showed an impressive stability in human plasma at 37°C (Figure 24a). While the two 
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exocyclic amino acids were cleaved by proteases, first the N-terminal serine (t1/2 = 29 min) followed 
by the C-terminal tyrosine (t1/2 = 6.9 hours), the double-bridged macrocycle core remained intact after 
two days.  
 
Figure 24. Stability of double-bridged peptides. a) Proteolytic degradation of PK2 (isomer 3) 
and PK6 (isomer 1) in human plasma analyzed by LC-MS. Total ion count (TIC) in SIM mode of 
identified species is shown. b) Inhibitory activities of N- or C-terminally modified PK2 (isomer 3). 
Average values and standard deviations of KIs were calculated from at least three measurements. c) 
LC-MS analysis of PK10 after incubation in human blood plasma. d) Fraction of functional PK10 
after incubation in human blood plasma as determined in a FXIIa inhibition assay. e) Inhibition of 
the intrinsic coagulation pathway. Coagulation time (aPTT) was measured in human blood ex vivo 
at different concentrations of the indicated plasma kallikrein inhibitors. – Data produced by Dr S. 
Kale. 
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The high stability of PK2 most likely results from interlaced bridging that tightly connects the 
two macrocycles, reducing their conformational flexibility and/or rendering them less accessible to 
proteases. This was confirmed by testing a peptide, PK6 (isomer 1), lacking the interlaced 
configuration due to bridges between Cys1/Cys2 and Cys3/Cys4, which was rapidly degraded (t1/2 ~ 5 
minutes; Figure 24b). For PK2, the loss of the terminal amino acids reduced the activity of the peptide 
4-fold (Ser1) and 108-fold (Tyr11), respectively (Figure 24c). To mitigate this loss, we tested a small 
set of peptides in which the vulnerable exocyclic residues were replaced by D-amino acids (Figure 
24c). Appending D-Arg at the N-terminus and D-Tyr at the C-terminus increased the inhibitory 
activity 1.9- and 9.6-fold, respectively. The resulting macrocycle PK10 had a KI of 3.6 ± 0.5 nM, 
compared to 0.5 ± 0.1 nM for the PK2 precursor, though remained fully intact upon incubation in 
plasma (t1/2 > 3 days; Figure 24c and d).  
?????? ????????????????????????????????????????????????
Plasma kallikrein plays a role in various diseases including hereditary angioedema (HEA), 
diabetic macular edema, and thrombosis, and contributes to contact activation in extracorporeal 
circulation during procedures such as coronary artery bypass grafting. Two protein-based inhibitors, 
C1 inhibitor and ecallantide, are approved for the treatment of acute HEA attacks136,137. Several drug 
development programs are ongoing to generate antibody (e.g. lanadelumab) or small molecule 
inhibitors of plasma kallikrein138,143. We tested if the double-bridged peptides could block the 
activation of the intrinsic coagulation pathway in human plasma, which is dependent on the 
reciprocal activation of plasma kallikrein and factor XII (FXII). Human plasma was incubated with 
inhibitor, the activation of FXII was triggered by Pathromtin?, and the time to coagulation was 
measured to determine the activated partial thromboplastin time (aPTT). The peptides PK2, PK4, 
PK6, and PK10 all efficiently inhibited activation of the intrinsic coagulation pathway in human 
plasma ex vivo (Figure 24e); PK10 doubled the aPTT (EC2x) at a concentration of 3 μM. 
3.4 – Discussion 
We show that macrocyclic peptide libraries with a large structural diversity can be generated 
by cyclizing peptides with two chemical bridges that each connect a pair of cysteines. This approach 
yielded libraries comprising far more different macrocyclic scaffolds than any previously developed 
libraries, which tend to be based on one or, at the most, a handful of different scaffolds. High-
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throughput sequencing of isolated peptides revealed a strong preference for certain peptide formats, 
clearly showing the importance of the large scaffold diversity. Even though the new strategy generates 
three macrocyclic isomers that are all encoded by the same phage DNA, we show that multiple 
products do not impair the phage panning procedure, that the three isomers can be efficiently 
synthesized with an orthogonal protection strategy, and that the active isomer can easily be identified.  
As a direct comparison, similarly sized bicyclic peptides (11 amino acids) that were cyclized by 
only one chemical linker (connecting three cysteines) were previously developed to the same target 
by screening the same type of library (XCX3CX3CX)77. The best bicyclic peptide plasma kallikrein 
inhibitor developed through these pans had a KI of 5.2 nM and thus a 10-fold weaker binding affinity 
than the di-bridged peptides. It is likely that the affinity improvement can be attributed to the larger 
scaffold diversity that was generated and sampled with the new approach. A plasma kallikrein 
inhibitor with a comparable affinity (KI = 0.3 nM) was previously obtained only by screening a library 
of much longer bicyclic peptides that form a larger binding interface with the target (15 amino acids 
of the form XCX5CX5CX cyclized by one linker)77. The development of smaller macrocycles with a 
molecular weight approaching 1 kDa is of interest for the development of drugs amenable to topical 
or oral administration. Several orally available peptide macrocycles, including vacomycin (1.5 kDa) 
and cyclosporin (1.2 kDa), have molecular weights in this range, suggesting that phage selected 
double-bridged peptides might be applied as leads for the development of topical or oral drugs. 
The SAR study revealed that both of the two chemical bridges in the bicyclic peptides are 
essential for binding, wherein one bridge was slightly more important in all of the examples studied. 
Substitution to structurally similar bridges reduced the binding affinity, suggesting that cyclizing 
peptide phage libraries in parallel with similar reagents such as compounds 13-19 will allow for the 
generation of even larger macrocycle diversities. A SAR study altering the amino acid sequence of 
double-bridged peptide PK2 showed that its high target selectivity was based, at least to some extent, 
on the specific peptide backbone architecture. None of the numerous amino acid mutations tested 
increased the affinity for the homologous protease FXIa. This is in stark contrast to the previously 
developed single-bridged bicyclic peptide inhibitors of plasma kallikrein that also inhibited FXIa 
when specific amino acid positions were mutated77. This observation is an additional indication that 
the larger scaffold diversity allowed for the identification of ligands that are perfectly complementary 
in shape and polarity to the target binding site. 
An interesting feature of the ligands with interlaced bridges is the high proteolytic stability. The 
core structure of PK2 resisted protease degradation when it was incubated for several days in human 
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plasma at 37°C. This high stability is likely due to the close connection of the two macrocyclic rings, 
resulting from interlacing bridges Cys1/Cys3 and Cys2/Cys4. This hypothesis is further supported by 
the low proteolytic stability of the double-bridged PK6 that contains two independent monocycles 
connected via a flexible linker. The enormous stability of the interlaced peptide macrocycle format 
might be exploited for the development of oral drugs that must survive the proteolytic pressure in the 
gastrointestinal tract. This could include either drugs that are absorbed into the bloodstream or that 
act on targets in the gastrointestinal tract. The feasibility of peptide-based drugs acting in the lumen 
of the gastrointestinal tract is demonstrated with the recently approved blockbuster drug linaclotide. 
This 14-amino acid peptide derived from nature and stabilized by three disulfide bridges is orally 
applied. The low stability for exocyclic amino acids, such as the Ser1 and Tyr11 in PK2, should 
therefore not be a limitation as they can be substituted to non-natural building blocks that resist 
proteolytic cleavage, as demonstrated in this work. Alternatively, exocyclic amino acids may be 
completely omitted and the loss in affinity compensated by substituting amino acids in the core to 
unnatural ones that can more efficiently bind the target. The latter strategy would allow a further 
reduction of the molecular weight of the ligands, and would reduce the size of PK2 to below 1 kDa. 
In summary, we have developed an efficient strategy for the generation and screening of 
macrocyclic peptide libraries comprising an unprecedented scaffold diversity. We show that ligands 
with a better affinity and target selectivity can be isolated from such libraries despite a rather small 
molecular mass of the compounds, and that a scaffold format with interlaced macrocyclic rings has a 
particularly high stability. The combined properties of the generated ligands including high affinity 
and selectivity, small size, and high proteolytic stability make them interesting as drug development 
leads. 
3.5 – Materials and methods 
Cyclization of model peptide with thiol-reactive reagents 
10 μL of thiol-reactive reagents at concentrations ranging from 500 μM to 32 mM in acetonitrile 
(ACN) were added to 40 μL of 50 μM of the peptide ACSRCVECGWCG-NH2 in NH4CO3 buffer (60 
mM, pH 8.0) and incubated for 1 h at 30°C. All linkers were commercially available except for linker 
7 which was synthesized as previously described77. Reactions were quenched with 40% formic acid 
(10 μL) and analyzed by LC-MS (LCMS-2020, Shimadzu). Injection volume: 1 μL, column: 
Kinetix®C18, 2.6 μm, 100 Å, 50x2.1 mm (Phenomenex), gradient: solvent A (99.95% H2O, 0.05% 
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formic acid) and 10-60% of solvent B (99.95% ACN, 0.05% formic acid) over 5 min, flow: 1 mL min-
1, MS analysis: positive mode. Potential detrimental effects of the thiol-reactive reagents on phage 
were assessed by incubating 1011 phage (transforming units, t.u.) with the reagents and measuring the 
number of infective phage. 20 μL of thiol-reactive reagents at concentrations ranging from 20 μM to 
3 mM in ACN were added to 80 μL of 1011 t.u phage in 60 mM NH4CO3 buffer pH 8.0, and incubated 
for 1 h at 30°C. The number of functional phage was quantified by infecting 20 μL of exponentially 
growing E. coli cells with 10-fold dilutions of the phage and plating the cells on selective agar plates 
(30 μg.ml-1 chloramphenicol). 
 
Phage selection of double-bridged peptides 
Phage of library 1 and 2 were produced in separate 1 L E. coli cultures, pooled, purified by PEG-
precipitation, and the cysteines in the peptides reduced as previously described144. Phage were 
dissolved in 50 mL aqueous buffer containing 20 mM NH4CO3, 5 mM EDTA, pH 8 and distributed 
into 6 tubes. The peptides were chemically modified by adding 2 mL of the cyclization reagents in 
ACN to 8 mL phage, and incubating for 1 h at 30 °C in a water bath. Modified phage were precipitated 
in 20% PEG, 500 mM NaCl, and dissolved in 3 mL washing buffer (10 mM Tris-Cl, pH 7.4, 150 mM 
NaCl, 10 mM MgCl2, 1 mM CaCl2, pH 7.4). Human plasma kallikrein (Molecular Innovations) was 
biotinylated by incubating the protease at a concentration of 10 μM with a 15-fold molar excess of 
EZ-Link? Sulfo-NHS-LC-Biotin (ThermoFisher Scientific) for 1 h at RT and the excess of 
biotinylation reagent was removed by size exclusion chromatography. 2.5 μg of biotinylated plasma 
kallikrein was incubated with 50 μL magnetic streptavidin beads (Dynabeads® M-280 Streptavidin, 
ThermoFisher Scientific) in 500 μL of washing buffer for 15 minutes and non-immobilized protein 
was removed by washing three times. Both, phage and the beads were separately blocked by the 
addition of 500 μl of washing buffer containing 1% w/v BSA and 0.1% v/v Tween 20, and incubated 
for 30 minutes. Phage and magnetic beads were mixed and incubated for 1 h on a rotating wheel at 
RT. The beads were washed eight times with washing buffer containing 0.1% v/v Tween 20 and twice 
with washing buffer only. Phage were eluted by incubating the beads with 100 μL of 50 mM glycine, 
pH 2.2 for 5 min. The solution containing the eluted phage was neutralized by the addition of 50 μL 
1 M Tris-Cl, pH 8.0 and added to 30 mL of exponentially growing TG1 E. coli cells (OD600 = 0.4). After 
a 90 min incubation, the freshly infected bacteria were plated on 2YT/chloramphenicol plates (30 μg. 
ml-1) and incubated overnight at 37°C. Bacterial cells of the colonies were recovered the next day in a 
small volume of 2YT media and stored as glycerol stocks at -80°C. The second round of selection was 
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performed using neutravidin-coated magnetic beads to prevent the enrichment of streptavidin-
specific peptides. Neutravidin beads were generated by coupling neutravidin to tosyl-activated 
magnetic beads according to the manufacturer’s recommended protocol (Dynabeads M-280 
Tosylactivated, Invitrogen Dynal Biotech AS).  
 
High-throughput DNA sequencing of enriched phage 
Phage DNA was extracted from E. coli cell pellets (around 50 mg) using a kit wherein the DNA was 
eluted with 5 mM Tris-HCl, pH 8.5. The DNA region encoding the peptides was amplified by PCR 
using 100 ng phage DNA as template, one of the following forward primers, and the reverse primer 
5'-CCTCTCTATGGGCAGTCGGTGATTTTCAACAGTTTCAGCGGAGTG-3'. Each primer 
contains a sequence for annealing to the phage vector (italics) and an adapter sequence for ion 
semiconductor sequencing. The forward primers contain a barcode that encodes the cyclization 
reagent used in the phage selection (underlined), allowing for pooled sequencing of all isolated phage 
and deconvolution. 
 
Bridge 1  5'-CCATCTCATCCCTGCGTGTCTCCGACTCAGCTCTGACGCAATTCCTTTAGTTGTTC-3’ 
Bridge 3  5'-CCATCTCATCCCTGCGTGTCTCCGACTCAGCGTCATCGCAATTCCTTTAGTTGTTC-3’ 
Bridge 4  5'-CCATCTCATCCCTGCGTGTCTCCGACTCAGATACTCCGCAATTCCTTTAGTTGTTC-3’ 
Bridge 7  5'-CCATCTCATCCCTGCGTGTCTCCGACTCAGGACTTACGCAATTCCTTTAGTTGTTC-3’ 
Bridge 10  5'-CCATCTCATCCCTGCGTGTCTCCGACTCAGTTCAGTCGCAATTCCTTTAGTTGTTC-3’ 
Bridge 12  5'-CCATCTCATCCCTGCGTGTCTCCGACTCAGCAGTTCCGCAATTCCTTTAGTTGTTC-3’ 
 
A standard PCR reaction was performed (25 cycles, 30 s 95°C, 30 s 55°C, 30 s 72°C) in a volume 
of 50 μL containing Taq polymerase buffer, 250 μM dNTP, 500 nM primer, and 1 unit Taq 
polymerase. Three additional PCR cycles were performed with fresh reagents wherein 10 μL of the 
first PCR reaction served as a template, in order to limit the amount of DNA heteroduplex. PCR 
products were separated by agarose gel electrophoresis (2.5% gel UltraPure agarose, Invitrogen), 
extracted using a kit, and DNA elution with 5 mM Tris-HCl, pH 8.5. Ion semiconductor sequencing 
was performed by the Centre for Research in Agricultural Genomics (Barcelona, Spain) on an Ion 
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Personal Genome Machine (PGMTM) sequencer. Sequence data was processed and sequences were 
aligned using MATLAB scripts120. 
 
Peptide synthesis 
Peptides were synthesized on an Advanced ChemTech 348Ω parallel peptide synthesizer (AAPPTec) 
by standard Fmoc solid-phase chemistry on Rink Amide MBHA resin (0.26 mmol/g resin, 0.03 mmol 
scale). The coupling was carried out twice for each natural amino acid (4 eq.) using HBTU (4 eq.), 
HOBt (4 eq.) and DIEA (6 eq.) in 1.3 mL DMF with shaking at 400 rpm for 30 min. The coupling of 
unnatural amino acids (2 eq.) was performed once using HATU (2 eq.) and DIEA (4 eq.) in 1.5 mL 
DMF and shaking at 400 rpm for 1 h. Fmoc groups were removed by incubating the resin twice with 
20% v/v piperidine in DMF with shaking 400 rpm for 5 min. Washing steps were performed with 3 
mL DMF. The resin was washed four times before Fmoc deprotection and five times after 
deprotection. 
 
Peptide cleavage and deprotection 
Final peptides were deprotected and cleaved from the resin under reducing conditions by incubation 
in 90% TFA, 2.5% H2O, 2.5% thioanisole, 2.5% phenol, 2.5% EDT with shaking for 4 h at room 
temperature. The resin was removed by vacuum filtration, peptides precipitated with cold diethyl 
ether (50 mL) and a 30 min incubation at -20°C, and pelleted by centrifugation at 4400 g for 5 min. 
The peptide pellets were washed twice with cold diethyl ether (30 mL) and lyophilized or directly 
purified by HPLC. 
 
Peptide cyclization by bridging random pairs of cysteines 
Purified peptide (9 mL, 1.2 mM) was dissolved in 40% v/v ACN and 60% v/v aqueous buffer (60 mM 
NH4HCO3, pH 8.0) and the cyclization reagent was added (1 mL, 40 mM in ACN). The final reagent 
and solvent concentrations in the reaction mixture were 1 mM peptide, 4 mM cyclization reagent, 
50% v/v aqueous buffer, and 50% v/v ACN. The reaction mixture was incubated at 30°C in a water 
bath for 1 h and then lyophilized. 
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Peptide cyclization by bridging specific pairs of cysteines 
Peptides with defined pairs of cysteines bridged by chemical linkers were synthesized as shown in 
Supplementary Figure 3.4 and described in the following. Peptides were synthesized on Rink amide 
resin as described above wherein the N-terminal Fmoc group was not removed. Two of the cysteines 
were protected at the side chain with Mmt and two with Dpm. After washing the resin with 5 mL 
DCM, the two cysteines with the Mmt groups were deprotected by shaking the resin in 5 mL of 
TFA:TIS:DCM (1:5:94) in a fritted syringe for 3 min. The solution was removed and the deprotection 
repeated 9 times. The resin was washed 3 times with DCM for 1 min and swollen by washing 4 times 
with DMF. 2 eq. of cyclization reagent in 3 mL DMF and 3 eq. of DIPEA in 1 mL were added together 
stepwise and the reaction shaken for 1 h at RT. The reaction solution was removed and the resin 
washed 4 times with DMF. The N-terminal amino group was deprotected by adding twice 3 mL of 
20% piperidine in DMF for 5 min and shaking. The resin was washed 4 times with DMF and subjected 
to global deprotection in 5 mL of the cleavage mixture TFA:TIS:EDT:H2O (97:1:1:2) for 12 h. In the 
case of linker 10 EDT was avoided in the cleavage mixture because of a reaction of EDT with the 
ketone group. The resin was filtered and peptide was precipitated by addition of 45 mL cold ether and 
incubation at -20 °C for 20 min. The peptide was pelleted by centrifugation at 4400 g for 5 min, washed 
twice with 30 mL ether and lyophilized. The crude peptide was dissolved in around 2 mL in a 1:1 
mixture of H2O and ACN to reach a concentration of 10 mM. 1.5 eq of cyclization reagent in 5 mL 
ACN and 9 mL of 60 mM NH4HCO3 pH 8 were added stepwise. If the solution was turbid, 4 mL of 
ACN were added. The reaction was incubated at 30 °C for 1 h. The reaction was quenched by addition 
of 1 mL of 40% HCOOH. The peptide was lyophilized and purified by RP-HPLC. 
 
Peptide purification 
Peptides were purified with a HPLC system (Prep LC 2535 HPLC, Waters) using a preparative C18 
reversed-phase column (SunfireTM prep C18 OBD 10 μm, 100 Å, 19x250 mm, Waters) or a semi-
preparative C18 reversed-phase column (X-bridge peptide BEH C18 5 μm, 300 Å, 10x250 mm, 
Waters) applying a flow rate of 20 or 6 mL.min-1 and a linear gradient of 10-50% v/v solvent B in 40 
min (A: 99.9% v/v H2O and 0.1% v/v TFA; B: 99.9% v/v ACN and 0.1% v/v TFA). Fractions containing 
the desired peptide were lyophilized. 
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Analysis of peptide purity and mass 
The purity was assessed by analyzing around 10 μg of peptide by RP-HPLC (1260 HPLC system, 
Agilent) using a C18 column (ZORBAX 300SB-C18, 5 μm, 300 Å, 4.6x250 mm, Agilent). Peptides 
were run at a flow rate of 1 mL.min-1 with a linear gradient of 0-100% or 0-50% v/v of solvent B over 
15 min (A: 94.9% v/v H2O, 5% v/v ACN and 0.1% v/v TFA; B: 94.9% v/v ACN, 5% v/v H2O and 0.1% 
v/v TFA). The mass of purified peptides was determined by electrospray ionization mass 
spectrometry (ESI-MS) in positive ion mode on a single quadrupole liquid chromatography mass 
spectrometer (LCMS-2020, Shimadzu). 
 
Protease inhibition assay 
Inhibition constants (KI) were determined by measuring the residual activities of protease in the 
presence of different dilutions of inhibitor (2-fold dilutions, ranging from 3 μM to 0.2 nM final 
concentration) using fluorogenic substrates. Activities were measured at 25°C in buffer containing 10 
mM Tris-Cl, pH 7.4, 150 mM NaCl, 10 mM MgCl2, 1 mM CaCl2, 0.1% w/v BSA and 0.01% v/v Triton-
X100 by monitoring the change in fluorescence intensity over one hour using a Tecan infinite M200 
Pro plate reader (excitation at 367 nm, emission recorded at 468 nm). All proteases were human in 
origin and were purchased from Molecular Innovations or Innovative Research and the following 
concentrations were used: 0.1 nM plasma kallikrein, 0.25 nM factor XIa, 2 nM factor XIIa, 2 nM 
thrombin, 1.5 nM uPA, 7.5 nM tPA, 2.5 nM plasmin, 6 nM factor Xa, 50 nM factor VIIa. The 
following fluorogenic substrates were used at 50 μM final concentration: Z-Phe-Arg-AMC for plasma 
kallikrein, Boc-Phe-Ser-Arg-AMC for factor XIa, Boc-Gln-Gly-Arg-AMC for factor XIIa, Z-Gly-Gly-
Arg-AMC for thrombin, uPA and tPA, H-D-Val-Leu-Lys-AMC for plasmin, D-Phe-Pro-Arg-
ANSNH-C4H9 for factor Xa and factor VIIa. The IC50 values were determined by fitting sigmoidal 
curves to the data using the following four-parameter logistic equation used for dose response curves: 
 
The KI values were calculated based on the IC50s using the Cheng-Prusoff equation. 
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Plasma stability measurement by quantifying functional inhibitor 
20 μM of peptide was incubated in human plasma (Innovative Research) at 37 °C in a water bath and 
30 μL probes were taken at different time points (5 min, 0.5, 1, 2, 4, 8, 24, and 48 h). The samples were 
diluted by addition of 770 μL assay buffer containing 0.1% (w/v) BSA and 0.01% (v/v) Triton-X100 
and the proteases were heat-inactivated by incubation at 69 °C for 20 min. The samples were stored 
at -20 °C. Residual inhibitor activity was measured using the protease activity assay described above. 
The samples were centrifuged at 16,000 g for 5 min and the supernatant was transferred to new tubes. 
Two-fold dilutions of the samples were prepared and the residual activity of 0.1 nM human plasma 
kallikrein was measured with 50 μM Z-Phe-Arg-AMC substrate as described above. Residual 
inhibition in % was calculated using the equation IC50,0h/IC50,xh*100 wherein IC50,0h is the functional 
strength of the inhibitor at time point 0 and IC50,xh the functional strength of inhibitor after one of the 
different plasma incubation periods mentioned above. The resulting percentages of inhibition were 
plotted versus time and analyzed using a one-phase exponential decay model. 
 
Plasma stability measurement by LC-MS analysis of bicyclic peptide 
40 μM of peptide was incubated in human plasma (Innovative Research) at 37 °C in a water 
bath. 5 μL probes were taken at different time points (5 min, 0.5, 1, 2, 4, 8, 24, and 48 h), diluted by 
addition of 5 μL 6 M guanidine hydrochloride pH 2 and incubated at RT for 30 min. The plasma 
proteins were precipitated by addition of cold ethanol (200 μL) and incubated for 30 min at -20 °C. 
The samples were centrifuged at 9000 g for 20 min, the supernatant was transferred to new tubes and 
the solvent was evaporated under vacuum (speed vac). The samples were dissolved in 20 μL of H2O 
and analyzed by LC-MS as described above. 
 
aPTT and PT experiment 
aPTT was determined in human plasma using a STAGO STart4 Coagulation analyzer (Diagnostica). 
Human single donor plasma was used (Innovative Research). 100 μL of plasma was incubated with 
100 μL of Pathromtin? SL (silicon dioxide particles, plant phospholipids in HEPES buffer system, 
Siemens) for 2 min at 37°C. The coagulation was triggered by addition of 100 μL CaCl2 solution (25 
mM, Siemens). Upon addition of this reagent the electromagnetically induced movement of a steel 
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ball in the plasma was monitored. The time until the ball stops moving was recorded as coagulation 
time. 
3.6 – Supplementary figures and tables 
 
Supplementary Figure 3.1. Scaffold diversity in libraries 1 and 2. Around 20% of peptides in 
library 1 (XCX3CX3CX-phage) and 23% of peptides in library 2 (XCX4CX4CX-phage) contain an 
additional cysteine in one of the random positions indicated with ‘X’. Cyclization with a chemical 
linker (indicated as a black ball) yields the indicated scaffolds. Random amino acids in the three 
segments are shown in red, orange and green. 
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Supplementary Figure 3.2. Abundance of peptide formats after panning library 2 cyclized 
with the indicated linkers against plasma kallikrein. Abundance is indicated in % of those 
peptides containing four cysteines. Abundance of peptide formats from library 1 is shown in Figure 
21a. 
 
Supplementary Figure 3.3. Consensus sequences. Peptides isolated from libraries 1 and 2 cy-
clized with the chemical linkers 1, 4, 7 and 12 after two rounds of selection. Peptides isolated with 
the chemical linkers 3 and 10 are shown in Figure 21b. 
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Supplementary Figure 3.4. Strategy for the synthesis of individual regioisomers of double-
bridged peptides. The first pair of cysteines is reacted on resin and the second pair in solution. 
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Supplementary Figure 3.5. Analytical RP-HPLC chromatograms of the plasma kallikrein 
inhibitors PK2 (isomer 3), PK4 (isomer 3), PK6 (isomer 1) and PK10 (isomer 3). Expected and 
measured molecular masses are indicated. 
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Supplementary Figure 3.6. Analytical RP-HPLC chromatograms of bicyclic peptide PK4 (isomer 
3) in which one of the two linkers was exchanged. The two numbers following the name “PK4” 
indicate the first and second linker, respectively. 
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Supplementary Figure 3.7. Analytical RP-HPLC chromatograms of bicyclic peptide PK6 (isomer 
1) in which one of the two linkers was exchanged. The two numbers following the name “PK6” 
indicate the first and second linker, respectively. 
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Supplementary Figure 3.8. Linker swapping. a) One of the two linkers of the bicyclic peptides 
PK4 (isomer 3) cyclized with linker 3 was replaced to either of five different linkers. b) One of the 
two linkers of the bicyclic peptides PK6 (isomer 1) cyclized with linker 3 was replaced to either of 
five different linkers. The residual activity of plasma kallikrein is shown. Values and standard devi-
ations were calculated based on three measurements. 
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Supplementary Figure 3.9. Analytical RP-HPLC chromatograms of bicyclic peptide PK2 (isomer 
3) variants in which one amino acid was substituted as indicated in the names. 
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4. Phage selection of head-to-side chain 
cyclized peptides allows for the 
generation of small cyclic peptide 
ligands 
?
?
This chapter is based on a manuscript that will be submitted for publication.  I 
will be the only first author in this publication.
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4.1 – Abstract 
The development of orally available peptide drugs has been a longstanding goal in the 
pharmaceutical industry. A major challenge towards this aim is the poor gastrointestinal absorption 
of the relatively large peptides. In this work, we aimed at developing cyclic peptide ligands with the 
smallest possible molecular weight; ideally well below 1 kDa to facilitate intestinal absorption. We 
applied a recently discovered peptide macrocyclization reaction in which the side chain of a cysteine 
is ligated with the N-terminal amino group to cyclize phage-encoded peptides of the form XXXC and 
XXXXC. Unlike other cyclization strategies that rely on the cyclization of two amino acid side chains 
(e.g. two cysteines to form a disulfide bridge), this approach requires only one constant amino acid - 
the cysteine, reducing the size of the peptides by one amino acid. Panning the libraries against the two 
disease targets plasma kallikrein and coagulation factor XIa yielded ligands with low micromolar 
affinities despite the small molecular weights around 750 Da. The approach should be applicable to 
many other disease targets and could potentially yield leads for the generation of orally available 
macrocycle drugs. 
4.2 – Introduction 
Cyclic peptides can bind with high affinity and selectivity to protein targets, making them an 
attractive modality for the development of therapeutics145,146. Cyclic peptide ligands can be identified 
for "challenging" targets that are not tractable to small molecules such as globular protein with 
featureless surfaces or protein-protein interactions. The good binding properties arise from their 
relatively large binding interface and the limited conformational flexibility imposed by the circular 
structure. Other strengths of cyclic peptides are the low toxicity of metabolic products, being mostly 
amino acids, as well as the ease of production by chemical synthesis. Cyclic peptides binding to 
virtually any targets of interest can be developed thanks to powerful in vitro display techniques such 
as phage display or mRNA display147–149. Several in vitro evolved cyclic peptides are currently tested 
in clinical trials26. 
A limitation of cyclic peptides is that they are typically not orally available. All the in vitro 
evolved cyclic peptides in clinical studies were developed for administration by injection. Given the 
obvious advantages of needle-free application, there is a high interest in developing orally available 
cyclic peptides. The reasons for the poor oral availability are degradation by proteases in the 
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gastrointestinal tract and/or poor absorption across the epithelium of the gastrointestinal tract. While 
proteolytic stability can be achieved relatively easily by modifying the peptide around the cleavable 
bonds through the introduction of unnatural amino acids or peptide bond surrogates, the poor 
absorption across the intestinal epithelium is more difficult to overcome. Key parameters are the 
molecular mass and the size of the polar surface13,126. The limited oral availability of several cyclic 
peptide drugs with a molecular weight around 1 kDa, as for example oxytocin (1007 Da, F = 0.9% in 
rat), actinomycin (1255 Da, F = 5% in human) or caspofungin (1093 Da, F < 0.2 %), illustrates that 
cyclic peptides should be smaller to achieve good uptake via the oral route.124 Omission of amino acids 
with polar side chains or N-methylation of peptide bonds can facilitate oral delivery. Studies with 
partially N-methylated cyclic pentapeptides show that good oral availability can be reached for 
molecules with a molecular weight around 600 Da, but that bioavailability depends on the specific 
peptide sequence.150 
In this work, we aimed at using phage display to generate cyclic peptide ligands that have the 
smallest possible molecular weight, ideally well below 1 kDa. A challenge in developing such small 
cyclic peptides is that they contain only a few amino acids, limiting the number of contacts that can 
be formed between cyclic peptide and protein target. Most peptide ligands developed by phage display 
or other in vitro display techniques contain more than ten amino acids. The smallest cyclic peptide 
ligand isolated by phage display is a six-amino acid peptide cyclized by a disulfide bridge that was 
isolated against streptavidin66. The peptide cyclo-Ac[CHPQFC]NH2 binds streptavidin with a Kd of 
270 nM. Slightly larger disulfide-cyclized peptides, containing seven or eight amino acids, were 
isolated against Neutravidin151, the paratope of an anti-somatostatin antibody152 and integrins153. A 
limitation of disulfide-cyclized peptides is that they require two constant amino acids - the cysteines 
– that cannot be varied in a combinatorial fashion but contribute together 240 Da to the molecular 
weight of the ligand. For instance, if the molecular weight of cyclic peptides is limited to 700 Da, the 
number of amino acids in a cyclic peptide should not exceed four or five. Given that two cysteines are 
required, the number of variable amino acids is thus limited to two or three and the maximal diversity 
of the libraries is thus only 400 for peptides of the format CXXC and 8,000 for peptides of the form 
CXXXC. 
Slightly smaller cyclic peptides can be generated if the peptides are cyclized by connecting a 
side chain with one of the peptide termini. We have recently discovered a chemical reaction in which 
peptides are efficiently cyclized by connecting the thiol side chain of a C-terminal cysteine with the 
amino group of the N-terminal amino acid (Kale, S. et al., unpublished). With this reaction, only one 
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of the amino acids is required for the cyclization instead of two. In short cyclic peptides of four or five 
amino acids, three or four amino acid positions remain for diversification, allowing a diversity of 
8,000 and 160,000 cyclic peptides, respectively. In this work, we chose to exploit the head-to-side 
chain cyclization to generate and screen large libraries of small cyclic peptides (Figure 25a). We 
reasoned that such peptides, even if they have only moderate binding affinity, could be used as lead 
structures for further optimization using unnatural amino acids to improve binding affinity, 
proteolytic stability and bioavailability. 
4.3 – Results 
?????? ????????????????????????????????????
We have cloned two phage display libraries encoding peptides of the form XXXC (library 1) 
and XXXXC (library 2; Figure 25a) as fusion with phage pIII. A mutated pIII was employed that lacks 
six cysteines present in the wild-type phage coat protein76, preventing reaction of other cysteines with 
the cyclization reagents. Degenerate primers containing NNK codons were used for the library 
construction to allow all 20 amino acids in the randomized positions. The theoretical numbers of 
different peptides in these libraries are 8,000 and 160,000, respectively. The number of bacterial cells 
that were transformed with a plasmid of the library exceeded 4.9 × 107 (library 1) and 3.2 × 107 (library 
2), ensuring that nearly all the possible sequences are represented in the two phage display libraries. 
We incubated phage of the two peptide libraries in separate reactions with eight different 
reagents that all contain two thiol-reactive groups (Figure 25b). These reagents react in a first step 
rapidly with the constant cysteine present in each peptide, and in a second step intra-molecularly with 
another nucleophilic group within the randomized region of the peptide154 (Figure 25a). If a cysteine 
is present in any of the random amino acids, the second reactive group of the linker reacts with the 
sulfhydryl group of this additional cysteine (Figure 25a, dashed arrow). Depending on the position of 
this cysteine in the peptide, three (library 1) or four (library 2) different cyclic peptide formats are 
generated. The number of different macrocycles that can be generated in this way is 3 x 400 (library 
1) and 4 x 8,000 (library 2) for one cyclization reagent, and a total of 9,400 macrocycles (library 1) and 
256,000 macrocycles (library 2), if the peptides are cyclized in parallel with the eight different reagents.  
If no cysteine is present in the random region, the second electrohilic group of the chemical 
linker can react with another, less nucleophilic group. As described above, we have recently found 
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that peptides containing one cysteine are efficiently macrocyclized by bivalent thiol-reactive reagents 
shown in Figure 25b by reacting first with the cysteine side chain and second with the N-terminal 
amino group (Kale, S. et al., unpublished). In this case, the number of different molecules generated 
is much larger, namely around 7000 (library 1) and 130 000 (library 2) for one cyclization reagent, 
and a total of more than 54,000 macrocycles (library 1) and 1,000,000 macrocycles (library 2), if the 
peptides are cyclized in parallel with the eight different reagents. Alternatively, the peptides may also 
be cyclized by connecting the side chains of the constant cysteine with a lysine, or with a methionine154 
(Figure 25a; dashed arrows). 
 
Figure 25. Phage selection of head-to-side chain cyclized short peptides. (a) Linear penta-
peptides displayed on phage (library 2), each containing one constant cysteine and four random 
amino acids are cyclized by a reagent having two thiol-reactive groups (RG). The reagent reacts first 
inter-molecularly with the thiol group of the cysteine and then intra-molecularly with a second 
electrophilic group such as the N-terminal amino group or the side chains of a second cysteine, a 
lysine or methionine. (b) Chemical reagents applied for the cyclization phage-displayed peptides. 
(c) Percentage of clones belonging to library 1 and 2 before the phage selection and after two rounds 
of phage selection against PK or FXIa. The numbers indicate the reagents used for the cyclization 
of the peptides on phage. 
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?????? ????????????????????? ???
We performed phage selections against the two serine proteases plasma kallikrein (PK) and 
coagulation factor XI (FXIa). Uncontrolled activity of plasma kallikrein causes the swelling disorder 
hereditary angioedema (HEA). While a protein-based inhibitor of PK, ecallantide, is approved for the 
treatment of HEA, no oral drug is yet available155. FXIa plays an important role in various thrombotic 
disorders and is an attractive target as it promises a safe anti-thrombotic therapy. As for PK, no small 
molecule drugs are available for FXIa. Phage of the two libraries were produced in separate E.coli 
cultures, purified by PEG precipitation and equal numbers of phage from each library were pooled. 
Around 1014 phage of the mixture were cyclized in eight separate reactions with the reagents shown 
in Figure 25b and panned against PK and FXIa in two iterative rounds of selection. Phage of the 
libraries 1 and 2 before selection and cyclization, and phage isolated in the 16 different selections, were 
identified by next generation sequencing (NGS; > 1 million reads for most samples). Peptides of the 
format XXXXC were strongly enriched over peptides of the format XXXC (Figure 25c). The 
enrichment of peptides from library 2 suggested that larger cyclic peptides bind substantially better 
than smaller ones. This most likely arises from the larger combinatorial diversity of library 2 and the 
larger interaction surface of these peptides. 
Using previously published MATLAB scripts, we analyzed the 500 most abundant clones of 
each selection by aligning them in groups of peptides that share sequence similarities111. Peptides 
containing an amber stop codon were strongly enriched in the selections. Sequencing of the library 
immediately after transformation of the plasmids into bacterial cells showed an equal distribution of 
all codons, including the UAG codon, showing that no bias was introduced during the library cloning 
(Supplementary figure 4.1). Sequencing of the library after phage production and before affinity 
panning revealed that the amber stop codon was enriched at this stage around 3-fold over other 
codons (Supplementary figure 4.1). The amber codon UAG is read as stop codon in around half of 
the translation events in the E.coli strain used. We speculate that cells harboring a phage clone with 
amber codon grow faster and that these clones were enriched during phage production but not in the 
phage affinity selection. We excluded peptides containing amber stop codons from the analysis. In 
most of the 16 selections, several consensus groups were identified (Figures 26 and 27). Given the 
redundancy of the genetic code, we expected abundant peptides to be encoded by several different 
DNA sequences. Indeed, for most peptides, different DNA sequences were identified, as indicated in 
the column "number of different DNA sequences" in Figures 26 and 27. The consensus sequences 
were different for peptides cyclized with the eight structurally diverse chemical linkers, suggesting that 
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the peptides were affinity-selected in a linker-modified form and thus most likely in a cyclic form. The 
consensus sequences found for the selections against PK and FXIa differed too, suggesting the 
isolation of target-specific ligands. 
 
Figure 26. Peptides selected against PK. For each selection, around one million of clones were 
sequenced and the most abundant 500 peptides aligned. Sequences are shown for those selections 
for which a consensus sequence was identified, or for which one clone was strongly enriched over 
all other library members. Sequence similarities are highlighted in color. The abundance of each 
sequence found by NGS is shown. For most peptides, multiple different DNA sequences were found 
due to codon degeneracy. Kis for linear and cyclic peptides were determined for selected clones. 
Indicated average values and standard deviations were calculated based on at least three 
measurements. 
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Figure 27. Peptides selected against FXIa. For each selection, around one million of clones were 
sequenced and the most abundant 500 peptides aligned. Sequences are shown for those selections 
for which a consensus sequence was identified, or for which one clone was strongly enriched over 
all other library members. Sequence similarities are highlighted in color. The abundance of each 
sequence found by NGS is shown. For most peptides, multiple different DNA sequences were found 
due to codon degeneracy. Kis for linear and cyclic peptides were determined for selected clones. 
Indicated average values and standard deviations were calculated based on at least three 
measurements. 
In several consensus sequences, particularly those identified in selections against PK, a second 
cysteine was present, indicating that the peptides were cyclized via two cysteine side chains. The 
additional cysteine was mostly found at the N-terminal end of the peptides, but also in the other 
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positions that were randomized. Peptides containing two cysteines were strongly enriched in the 
selections (see "abundance" in Figures 26 and 27), possibly because the chemical cyclization via two 
cysteines is more efficient than the cyclization via another pair of nucleophiles, and more phage carry 
the desired product. Some of the consensus sequences without a second cysteine contained a 
methionine at the N-terminus that had potentially reacted with the chemical linkers to form a 
sulfonium ion. Most consensus sequences did not contain an amino acids with a nucleophilic group 
in the side chain, suggesting that they were either isolated as cyclic peptides in which the C-terminal 
cysteine was linked by a chemical bridge to the N-terminal amino group, or they were isolated as 
linear peptides. 
?????? ??????????????????????????????????????????
We synthesized peptides from different formats and consensus groups with the aim of testing 
if the peptides bind in their cyclic or linear form, and to determine their binding affinity. A range of 
peptides selected based on abundance and consensus group were synthesized by solid phase peptide 
chemistry and purified. A fraction of the linear peptides was saved for testing the binding of the linear 
forms while the rest of the compounds was reacted with the appropriate cyclization reagent and finally 
purified by reversed phase HPLC (Supplementary figures 4.2 to 4.6). Assuming that most of the 
peptides were binding to the active sites of the two proteases, as found previously for selections with 
bicyclic peptides77,83, we tested the binding in inhibition assays using fluorogenic and chromogenic 
substrates of PK and FXIa (Supplementary figure 4.7). Among the peptides isolated against PK, all 
five peptides synthesized inhibited the protease, with KIs in the micromolar range. The peptides 
belong to three different consensus groups, all containing two cysteines cyclized via the linker 1 or 3 
and an arginine residue that most likely binds to the S1 pocket of the trypsin-like serine protease. All 
four cyclic peptides inhibited PK at least 10-fold better than their linear counterparts, suggesting that 
they were isolated in their cyclized form during the phage panning. The best inhibitors, PK1 and PK2 
cyclized with compound 1 inhibited PK with KIs of 11 ± 1 μM and 13 ± 1 μM, respectively.  
Among peptides isolated against FXIa, six out of the 15 tested cyclic peptides inhibited the 
protease with single-digit micromolar inhibition constants. The same peptides being not cyclized did 
not inhibit FXIa at the highest concentration tested (1 mM), clearly indicating that the peptides had 
been cyclized on phage and isolated in their cyclic form. The six peptides belong to two consensus 
groups, both containing only the constant C-terminal cysteine. Peptides of one of the consensus 
groups (MAXRC) contain a methionine at the N-terminus, and are potentially cyclized via the 
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methionine side chain. The two cyclic peptides of this group, FXI7 and FXI8 cyclized with linker 6 
inhibited FXIa with KIs of 8.8 ± 1.5 μM and 7.4 ± 0.3 μM. Peptides of the other consensus group 
(XHPWC) are cyclized via the side chain of the constant cysteine and the N-terminal amino group. 
The best inhibitor, FXI9 blocked FXIa with a KI of 1.7 ± 0.4 μM while its linear analogue did not 
inhibit the protease at a 1000-fold higher concentration. 
4.4 – Conclusions 
To our knowledge, the cyclic peptide ligands developed here are smaller than any cyclic 
peptide previously evolved by phage display. The small size was achieved by limiting the number of 
randomized amino acids to four and by applying a new head-to-side chain macrocyclization reaction 
that requires only a single constant amino acid, the cysteine. With the new strategy, we generated large 
libraries comprising more than a million different cyclic peptides that have an average molecular 
weight smaller than 750 Da. We show that the thiol-to-amine ligation reaction is compatible with 
phage display by isolating ligands that i) converge to consensus sequences possessing only one 
cysteine and ii) bind only when cyclized by a linker via the cysteine side chain and the N-terminus. 
The phage selections against two important disease targets, PK and FXIa yielded ligands with decent 
binding affinities in the low micromolar range. The approach and libraries should be applicable to 
other protein targets in order to identify small cyclic peptide leads to a broad range of targets. The 
affinity, stability, oral availability and other properties may be optimized in iterative rounds of 
improvement following established strategies that are routinely used to translate linear peptide leads 
into peptidomimetic drugs. 
4.4?– Materials and methods 
Cloning peptide phage display libraries 
The phage peptide libraries 1 and 2 were cloned by ligating DNA coding for the variant peptides, a 
GSG linker and the cysteine-free N-terminal domains D1 and D2 of p3 into the phage vector 
fd0D12144, between the leader peptide sequence and the C-terminal domain of pIII. The DNA coding 
for the N-terminal domains of pIII was amplified in a PCR reaction using the following pair of 
forward and reverse primers and the vector fdg3p0ss2176 as template: 
Prepcr1Clib: 5'-TGTGGTTCTGGCGCTGAAACTGTTGAAAGTAG-3' 
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sfinotfo: 5'-CCATGGCCCCCGAGGCCGCGGCCGCATTGACAGG-3' 
The PCR product was separated by electrophoresis on an agarose gel and the DNA extracted with a 
gel purification kit. DNA coding for diverse peptides of the formats XXXC and XXXXC was appended 
to the PCR product in a second PCR using the following degenerate forward primers, reverse primer 
and the product of the first PCR reaction as template: 
PCRlib1: 5'-TATGCGGCCCAGCCGGCCATGGCANNKNNKNNKTGTGGTTCTGGCGCTG-3' (library 1) 
PCRlib2: 5'-TATGCGGCCCAGCCGGCCATGGCANNKNNKNNKNNKTGTGGTTCTGGCGCTG-3' (library 2) 
sfinotfo: 5'- CCATGGCCCCCGAGGCCGCGGCCGCATTGACAGG-3' 
The final PCR products were digested with the restriction enzyme SfiI and ligated into the vector 
fd0D12 that was linearized by sequential digestion with EcoRI and SfiI. The ligated vector was 
electroporated into E.coli TG1 electrocompetent cells (Lucigen). After the transformation, the cells 
were rescued with SOC medium, incubated 1 h at 37°C and plated on large chloramphenicol plates 
(30 μg/ml). The bacteria were detached from the plates by suspension in 2xYT medium containing 
20% glycerol and stored in stocks of 1 mL at -80°C. The number of transformants was estimated based 
on the number of colonies growing on selective plates after plating various dilutions of transformed 
cells. 
 
Chemical cyclization of peptides on phage 
Phage were produced and modified as described before (Kale,S. et al., unpublished). Four 2 L flasks 
containing each 0.5 L of 2xYT medium supplemented with 30 μg/mL chloramphenicol were 
inoculated with TG1 E.coli cells harboring library 1 and 2 (2 flasks each) to reach an OD600 of 0.1. 
After overnight incubation for phage production (30°C, 200 rpm), phage were PEG-precipitated, 
dissolved in reaction buffer (20 mM NH4CO3, 5 mM EDTA, pH 8 ) and the two libraries pooled. The 
cysteines of the peptides were reduced by incubating the phage with 1 mM TCEP at 42°C for 1 h. The 
phage were concentrated in centrifugation tubes at 4°C and diluted with ice cold reaction buffer to 
lower the TCEP concentration below 10 μM. The phage were split into eight equal fractions and each 
fraction complemented with reaction buffer to a volume of 800 μL. 200 μL of the 0.2 mM cyclization 
reagents in ACN were added to reach a reagent concentration of 40 μM. After incubation at 30°C for 
1 h, excess reagent was removed by precipitating the phage with PEG. The pellet was dissolved in 
washing buffer (10 mM Tris-Cl, pH 7.4, 150 mM NaCl, 10 mM MgCl2, 1 mM CaCl2, pH 7.4) 
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containing 1% bovine serum albumin (BSA) and 0.01% tween 20. For the second round of panning, 
phage were produced in volumes of 25 mL cultures. 
 
Affinity selection against PK and FXIIa 
Human PK (activated protease; HPKA, Molecular Innovations) and FXIa (activated protease; 
HFXIA, Molecular Innovations) were biotinylated by incubating 0.2 mg protein (10 μM) in PBS 
buffer pH 7.4 with a 10 -fold molar excess of sulfo-NHS-LC-biotin (ThermoFisher) at RT. Unreacted 
biotinylation reagent was removed by size exclusion chromatography using a disposable PD10 
desalting column (GE Healthcare) and PBS buffer. For each selection, 1 μg biotinylated protease was 
immobilized on 50 μL of streptavidin-coated magnetic beads (streptavidin Dynabeads M-280®; 
ThermoFischer). The beads and free biotin binding sites were blocked with washing buffer containing 
1% BSA, 0.01% Tween 20 and 1 μM biotin in order to prevent the isolation of binders to streptavidin 
or the bead surface. For each target and linker, 200 μL of phage and 50 μL of blocked beads were mixed 
together and incubated 1 h at RT. Unbound phage were removed by washing the beads six times with 
washing buffer containing 0.01% Tween 20 (v/v) and twice with washing buffer. The remaining phage 
were eluted by incubating the beads 5 min with 100 μL of 50 mM glycine, pH 2.2. The solution 
containing the eluted phage was neutralized with 100 μL of 1 M Tris-Cl, pH 8.0, added to 25 mL of 
exponentially growing TG1 E.coli cells (OD600 = 0.4) and incubated for 90 min at 37°C. The cells were 
plated on chloramphenicol plates (30 μg/mL) and incubated overnight at 30°C. Cells of the colonies 
were harvested the next day with 2xYT containing 20% glycerol. The second round of selection was 
performed following the same procedure but using neutravidin-coated magnetic beads (25 μL) to 
prevent enrichment of streptavidin-binding peptides. Magnetic neutravidin beads were generated by 
coupling neutravidin to tosyl-activated magnetic beads (Dynabeads M-280 Tosylactivated; 
Thermofisher) as described before144. 
 
 
 
High-throughput DNA sequencing 
DNA released from phage particles or DNA isolated from infected bacterial cells was sequenced using 
NGS Illumina technology as described in the dedicated chapter 5. Double-stranded DNA from 
Chapter 4 – Phage selection of head-to-side chain cyclized peptides allows for the generation of small cyclic peptide ligands 
84 
infected bacterial cells was obtained by centrifugating 300 μL glycerol stock and extracting plasmid 
DNA from the cell pellet using a purification kit (NucleoSpin Plasmid, Macherey-Nagel). The phage 
DNA was amplified in two consecutive PCR reactions as described in the following. In the first 
reaction, the forward and reverse primers below were used. A 30 μL PCR reaction was performed 
adding reagents in the following order to achieve the final concentrations indicated in brackets. 20.4 
μL H2O, 6 μL 5x standard HF buffer, 0.9 μL DMSO, 0.6 μL dNTP (250 μM), 0.6 μL primer mixture 
(the 10 primers were pre-mixed, 40 nM of each primer; 400 nM in total), 0.5 μL Phusion? high-
fidelity DNA polymerase (1 unit; NEB), and 1 μL phage (1010 t.u.) or plasmid DNA (100 ng). 25 PCR 
cycles were performed (98°C for 15 sec, 55°C for 30 sec and 72°C for 15 sec). Formation of product 
was assessed by agarose gel electrophoresis (2.5%). 
 
Primer for 1st PCR reaction: 
NGS Forward1 5’-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGATTCTATGCGGCCCAGC-3' 
NGS Forward2 5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNATTCTATGCGGCCCAGC-3' 
NGS Forward3 5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNATTCTATGCGGCCCAGC-3' 
NGS Forward4 5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNATTCTATGCGGCCCAGC-3' 
NGS Forward5 5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNATTCTATGCGGCCCAGC-3' 
NGS Reverse1 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGTTTCAGCGCCAGAACC-3' 
NGS Reverse2 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGNTTTCAGCGCCAGAACC-3' 
NGS Reverse3 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGNNTTTCAGCGCCAGAACC-3' 
NGS Reverse4 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGNNNTTTCAGCGCCAGAACC-3' 
NGS Reverse5 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGNNNNTTTCAGCGCCAGAACC-3' 
A second PCR was performed to append barcodes to DNA from different samples and to append 
DNA sequences required for Illumina sequencing. In the primers shown below, the regions of the 
barcodes are underlined. A 60 μL PCR reaction was performed adding reagents in the following order 
to achieve the final concentrations indicated in brackets. 41.2 μL H2O, 12 μL 5x standard HF buffer, 
1.8 μL DMSO, 1.2 μL dNTP (250 μM), 0.6 μL Phusion? high-fidelity DNA polymerase (0.6 unit; 
NEB), 0.6 μL forward and reverse primer (400 nM) and 2 μL product of the 1st PCR. PCR products 
were purified from a 2.5% agarose gel (UltraPure agarose, Invitrogen) using a commercial agarose gel 
purification kit (QIAquick Gel Extraction Kit, Qiagen). DNA was eluted with 10 mM Tris-HCl, pH 
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8.5. Libraries were subsequently loaded at 1.5 pM on a Mid Output flow cell (Illumina) and sequenced 
with a NextSeq 500 instrument (Illumina) according to manufacturer instructions, yielding paired-
end reads of 75 nucleotides. Overlapping paired-end reads were merged using CLC Genomics 
Workbench v9.5 (Qiagen). The DNA was sequenced along with at least 30% of unrelated non-
amplicon-based libraries to avoid low-diversity problems that could occur on the Illumina NextSeq 
500 instrument. 
Primer for 2nd PCR reaction: 
NGS 2nd Forward S507   5'-AATGATACGGCGACCACCGAGATCTACACAAGGAGTATCGTCGGCAGCGTC-3' 
NGS 2nd Forward S520   5'-AATGATACGGCGACCACCGAGATCTACACAAGGCTATTCGTCGGCAGCGTC-3' 
NGS 2nd Reverse N704   5'-CAAGCAGAAGACGGCATACGAGATGCTCAGGAGTCTCGTGGGCTCGG-3' 
NGS 2nd Reverse N705   5'-CAAGCAGAAGACGGCATACGAGATAGGAGTCCGTCTCGTGGGCTCGG-3' 
NGS 2nd Reverse N706   5'-CAAGCAGAAGACGGCATACGAGATCATGCCTAGTCTCGTGGGCTCGG-3' 
NGS 2nd Reverse N707   5'-CAAGCAGAAGACGGCATACGAGATGTAGAGAGGTCTCGTGGGCTCGG-3' 
NGS 2nd Reverse N714   5'-CAAGCAGAAGACGGCATACGAGATTCATGAGCGTCTCGTGGGCTCGG-3' 
NGS 2nd Reverse N715   5'-CAAGCAGAAGACGGCATACGAGATCCTGAGATGTCTCGTGGGCTCGG-3' 
NGS 2nd Reverse N716   5'-CAAGCAGAAGACGGCATACGAGATTAGCGAGTGTCTCGTGGGCTCGG-3' 
NGS 2nd Reverse N719   5'- CAAGCAGAAGACGGCATACGAGATTACTACGCGTCTCGTGGGCTCGG-3' 
The sequencing data were analyzed using MATLAB scripts described in the dedicated chapter 5. The 
500 most abundant clones were compared to identify consensus sequences using the script 
clustering.m. 
 
Peptide synthesis 
Peptides were synthesized on an Intavis Multipep RSI synthesizer using a standard protocol for Fmoc 
solid phase chemistry. Each amino acid (4 equivalents, 0.5 M final concentration) was coupled twice 
for 30 min on 0.05 mmol of Rink amide resin using HBtU/HOBt (4 equivalent each) and N-
methylmorpholine (8 equivalents) as a base in a volume of 0.85 mL DMF. The resin was washed twice 
with 6 mL DMF after each coupling reaction. Unreacted amino groups were capped by addition of 
5% (v/v) acetic anhydride and 6% (v/v) 2,6-lutidine in 0.8 mL DMF for 5 min. The resin was washed 
7 times with 6 mL DMF. Fmoc protecting groups were removed by incubating the resin twice in 0.8 
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ml 20% (v/v) piperidine in DMF for 30 min. The resin was washed 7 times with 6 mL DMF. At the 
end of the synthesis, the resin was washed twice with 6 mL DCM. 
Peptides were cleaved from the resin and deprotected by incubation of the resin with 5 ml of cleavage 
mixture (TFA/phenol/water/thioanisole/ethanedithiol = 90/2.5/2.5/2.5/2.5) for 2 h with shaking. The 
resin was removed by filtration and the peptides were precipitated by addition of 50 mL of ice cold 
Et2O and incubation for 1 h at -20°C. The precipitated peptides were pelleted by centrifugation at 
2700 g for 10 min. The Et2O supernatant was discarded and the remaining solvent was evaporated at 
RT.  
Crude peptide (typically 10-15 mg) was dissolved in 10 ml H2O containing 0.1 % TFA and purified 
on a preparative C18 column (Vydac C18 TP1022 250 × 22mm, 10 mm) using a linear gradient of 
solvent B (99.9% v/v MeCN and 0.1% v/vTFA) over solvent A (99.9% v/v H2O, 0.1% v/v TFA) (28 
min, 0-20%, flow rate of 20 mL/min). Fractions containing the desired product were identified by ESI-
MS in positive ion mode on a single quadrupole liquid chromatography mass spectrometer (LCMS-
2020, Shimadzu) and lyophilized. Typically, 5-10 mg of purified peptide was obtained. 
 
Peptide cyclization 
Purified linear peptides (typically 4-5 mg) were cyclized by incubation with an excess of linker 
in aqueous buffer (60 mM NH4HCO3, pH 8) containing 20% MeCN for 1h at 30°C. Peptides 
containing two cysteines were cyclized at a concentration of 1 mM with 1.2 equivalents of linker. 
Peptides containing one cysteine were cyclized at a concentration of 100 μM with 8 equivalents of 
linker. After verification of the cyclization reaction by LC-MS (LCMS-2020, Shimadzu), the solvent 
was evaporated using lyophilization, the peptide dissolved in 10 mL of 99.9 % H2O/0.1 % TFA and 
purified by HPLC using a preparative C18 column (Vydac C18 TP1022 250 × 22mm, 10 mm) and a 
linear gradient of solvent B over solvent A (28 min, 0-25%, flow rate of 20 mL/min). The purity was 
assessed by analyzing around 20 μg of peptide by RP-HPLC (Agilent 1260 HPLC system) using a C18 
column (Agilent ZORBAX 300SB-C18, 4.6 × 250 mm, 5 μm) and a linear gradient (15 min, 0-30%, 
flow rate of 1 mL/min) of solvent B over solvent A’ (94.9% v/v MECN, 5% v/v H2O and 0.1% v/v TFA).  
Protease inhibition assay 
Inhibitory activities were determined by incubation of PK or FXIa with different concentrations of 
the linear and cyclic peptides and quantification of the residual activities. The activity assays were 
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performed in washing buffer containing 0.1% w/v BSA and 0.01% v/v Triton-X100 at 25°C. Activity 
of PK (0.1 nM) was measured with the fluorogenic substrate Z-Phe-Arg-AMC at a final concentration 
50 μM) and recording of the fluorescence intensity over 30 min (excitation at 367 nm, emission at 468 
nm) on a Tecan infinite M200 Pro plate reader. Activity of FXIa (1 nM) was measured with the 
chromogenic substrate Pyr-Pro-Arg-pNA at a final concentration 400 μM and recording of the 
absorbance at 405 nm on a Tecan infinite M200 Pro plate reader. IC50 values were calculated by 
fitting the Hill equation to the data using GraphPad Prism 5 software. The inhibitory constant (KI) 
was calculated according to the Cheng–Prusoff equation: KI  = IC50/(1+([S]0/Km)), where [S]0 is the 
total substrate concentration, and Km is the Michaelis–Menten constant (165 μM for PK and 260 μM 
for FXIa). 
4.5?– Supplementary figures 
 
 
 
Supplementary figure 4.1. Amino acids in the random region of peptides of library 2. The 
frequency of codons was determined by sequencing thousands of plasmids after electroporation of 
library 2 into bacterial cells (double-stranded phage vector isolated from bacteiral cells grown as 
colonies) or after phage production (single-strated phage DNA from phage particles), and 
compared to the theoretically expected frequency based on codon degeneracy. 
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Supplementary figure 4.2. Cyclic peptides selected against PK. Purified linear and cyclic pep-
tides were analyzed by HPLC. 
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Supplementary figure 4.3. Cyclic peptides selected against FXIa. Purified linear peptides were 
analyzed by HPLC. 
?
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Supplementary figure 4.4. Cyclic peptides selected against FXIa. Purified cyclic peptides were 
analyzed by HPLC. 
?
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Supplementary figure 4.5. Cyclic peptides selected against PK. Purified cyclic peptides were 
analyzed by mass spectrometry. 
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?
?
Supplementary figure 4.6. Cyclic peptides selected against FXIa. Purified cyclic peptides were 
analyzed by mass spectrometry. 
?
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?
?
Supplementary figure 4.7. Inhibition of PK and FXI by linear and cyclic peptides. For peptides 
showing > 50% inhibition at a concentration of 1 mM, the Hill equation was fit to the data. 
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5. Bypassing bacterial infection in 
phage display by sequencing DNA 
released from phage particles 
?
?
This chapter is based on a manuscript that has been submitted for publication 
and is currently under review. I will be the only first author in this publication.   
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5.1 – Abstract 
Phage display relies on a bacterial infection step in which the phage particles are replicated to 
perform multiple affinity selection rounds and to enable the identification of isolated clones by DNA 
sequencing. While this process is efficient for wild-type phage, the bacterial infection rate of phage 
with mutant or chemically modified coat proteins can be low. For example, a phage mutant with a 
disulfide-free pIII coat protein, used for the selection of bicyclic peptides, has a more than 100-fold 
reduced infection rate compared to the wild-type. A potential strategy for bypassing this bacterial in-
fection step is to directly sequence DNA extracted from phage particles. In this work, high-through-
put sequencing was used to quantify the fraction of phage clones that can be identified by directly 
sequencing DNA from phage particles. The results show that the DNA of essentially all of the phage 
particles can be "decoded", and that the sequence coverage for mutants equals that of plasmid DNA 
extracted from cells infected with wild-type phage. This procedure is particularly attractive for selec-
tions with phage that have a compromised infection capacity, and it may allow phage display to be 
performed with particles that are not infective at all. 
5.2 – Introduction 
Phage display is a powerful in vitro screening technique that allows for the identification of 
ligands from large libraries of peptides or proteins. Each member of a library is displayed on the 
surface of a phage as a fusion with a coat protein, and the encoding gene is enclosed in the phage 
particle. Ligands are isolated from the libraries in iterative rounds of in vitro panning and 
amplification and are subsequently identified by sequencing the phage DNA. The phage amplification 
and sequencing steps rely on bacterial infection in which the phage binds to a cell and injects its DNA 
into the cytoplasm. For phage propagation, the cells synthesize copies of single-stranded DNA 
(ssDNA) and phage proteins that are assembled into new phage particles. For sequencing, typically 
circular phage DNA replicated by the bacterial cells is isolated. For filamentous phage, more than half 
of the particles of a phage preparation can infect bacterial cells156, indicating that the infection is highly 
efficient. This high efficiency ensures that essentially all ligands isolated in a phage panning 
experiment can be amplified or identified, making phage display a highly effective method for ligand 
identification. 
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The bacterial infection step can be compromised in some phage selection systems for different 
reasons. First, the infectivity of filamentous phage can be reduced when large guest proteins are fused 
to the pIII and impair the interaction of the pIII with the F-pilus and/or TolA of bacterial cells156 or 
when the displayed proteins are not properly folded and the fusion proteins, including the N-terminal 
domains of pIII, are proteolytically degraded157. Second, some phage selection procedures require a 
mutated coat protein. For example, a filamentous phage developed by Schmidt and co-workers that 
is lacking disulfide bridges in the pIII has a substantially reduced infectivity76, with only around one 
out of 100 phages able to infect bacterial cells. This phage clone is applied for the selection of bicyclic 
peptides that are generated by chemically cyclizing linear peptides via three cysteines contained in the 
ligand sequence prior to affinity selection68. Third, the infectivity of phage can be reduced after 
exposure to reagents that are applied to modify peptides or proteins displayed on phage. For example, 
in the generation of bicyclic peptides, the reagent 1,3,5-tris(bromomethyl)benzene (TBMB) applied 
at a concentration of 10 μM typically reduces the number of infective phage 3 to 10-fold78. Other 
chemical transformations using harsher reaction conditions may reduce the infectivity by larger 
factors158–160. A compromised infection rate can negatively affect the phage display selection process. 
First, not all clones will be propagated during the phage selection. Second, several studies have 
reported biases that are introduced in the step of phage infection and/or propagation122,161,162, and 
these biases may be more pronounced if the efficiency of the infection step is reduced. 
The development of high-throughput sequencing techniques has enabled the identification of 
millions of clones after a phage selection. These techniques have been applied for identifying 
antibodies, protein domains, and peptides that were isolated by phage display163–165. Sequencing such 
a large number of clones allowed for the identification of binders immediately after a single round of 
phage display, omitting the infection step necessary for phage amplification for subsequent 
rounds112,120. This in turn has reduced the number of bacterial infections needed in a phage display 
selection process to a single one – the one required for the sequencing step. 
Sequencing the DNA extracted from phage particles could in principle omit this step of 
bacterial infection completely. ssDNA purified from phage particles has been used routinely as a 
template for sequencing phage DNA166. The DNA in intact phage can also be efficiently amplified by 
incubating whole phage particles in a PCR reaction, as the capsids disassemble during the 
denaturation step to expose the DNA167. This method, termed "whole phage PCR", was applied for the 
direct sequencing of peptides in phage selections168. While a large number of clones could be 
sequenced with this method, it was unclear which fraction of the total phage clones could actually be 
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identified. An idea about the efficiency of the PCR amplification of DNA from phage particles can be 
obtained from quantitative PCR (qPCR) using phage particles as a template. Dias-Neto et al. showed 
that the DNA of samples containing as few as 10 phage particles can be identified with a readable 
signal in qPCR108. 
In our work, we measured what fraction of phage clones can be decoded by directly sequencing 
DNA from phage particles. This procedure was compared with a strategy in which plasmid DNA, 
obtained from cells infected with wild-type phage, was sequenced. It was shown that the sequencing 
of phage particle DNA is highly efficient and can identify approximately the same number of clones 
as when a bacterial infection step is used before the sequencing. 
5.3 – Results 
?????? ??????????????????????????????????
For assessing the fraction of phage that can be identified by sequencing the DNA released from 
phage particles, the absolute number of phage particles in a sample had to be determined. Wild-type 
fd phage displaying a library of random peptides was produced and purified by PEG precipitation 
(peptides of 14 amino acids fused to pIII, diversity > 109). The t.u. was 7.3 × 1013 ± 1.4 × 1013 per 
milliliter as determined by infecting exponentially growing E. coli TG1 cells with serial dilutions of 
the sample and counting colonies grown on selective plates. The number of phage particles was 
determined by measuring the absorbance using two related protocols, one based on the absorbance 
of intact phage particles at 269 nm169 and one based on the absorbance of extracted ssDNA at 260 nm. 
In the latter method, phage were incubated at 95°C and precipitated coat proteins were removed by 
centrifugation. The two methods gave similar phage particle concentrations of 7.2 × 1013 ± 0.3 × 1013 
and 6.5 × 1013 ± 0.2 × 1013 per milliliter, respectively. These numbers of physical phage particles were 
close to the number of infective phage. 
?????? ??????????????????????????????????????????????????????
The quantity of ssDNA that is released from the phage particles upon dissociation of the coat 
protein by heating was determined by qPCR. Purified phage plasmid DNA was used as a standard. 
Threefold serial dilutions of plasmid DNA and phage were subjected to 40 cycles of qPCR using a 
Taqman probe for signal detection (Figure 28a). The reactions with the highest and lowest 
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concentrations were prepared to contain 100,000 and 5 molecules of plasmid DNA and phage 
particles, respectively. The qPCR measurements were performed in duplicate. Cycle threshold (Ct) 
values were plotted against the number of molecules (plasmid DNA or phage particles) on a 
logarithmic scale (Figure 28b). For both, plasmid DNA and phage particles, a correlation coefficient 
of 0.997 was found. Amplification slopes of -3.65 and -3.30 indicated an amplification efficiency of 
more than 88%. The Ct values for identical dilutions of plasmid DNA and phage were similar, 
indicating that DNA was quantitatively released from the phage particles and that it was efficiently 
used as a template in the PCR reaction. Even in the reaction containing five phage particles, DNA 
could be released and amplified. This important step suggested that bacterial replication of DNA is 
not a requirement for phage display sequencing, and that DNA amplification can be efficiently 
accomplished solely by PCR using eluted phage particles as template. 
 
Figure 28. Quantification of ssDNA released from phage particles using qPCR. a) qPCR 
amplification of plasmid DNA and DNA from phage particle. Threefold dilutions of plasmid DNA 
and phage were prepared and qPCR reactions were performed in duplicate. Curves from duplicates 
were overlapping and only one dataset is shown for clarity. b) Cycle threshold (Ct) values are 
Chapter 5 – Bypassing bacterial infection in phage display by sequencing DNA released from phage particles 
101 
plotted against the number of molecules (plasmid DNA or phage particles) on a logarithmic scale. 
Correlation coefficients and slopes are indicated. 
?????? ??????????? ????????????????????????????????
The number of phage clones that could be identified by sequencing DNA released from phage 
particles was quantified by NGS using Illumina technology. Dilutions of the peptide phage library 
described above were prepared so that samples contained approximately 7, 70, 700, 7000, or 70,000 
phage particles. The phage peptide library used contains a diversity greater than 109 so that essentially 
all samples, even the one with as many as 70,000 phage, contains clones that are all different. For 
comparison, equivalent dilutions of plasmid DNA were prepared.  
 
Figure 29. DNA primers for the sequencing of phage clones by Illumina NextSeq technology. 
a) The region of the phage DNA covering the leader sequence, the peptide, and the N-terminal end 
of pIII is shown. Library peptides contain 14 amino acids (m + n + o = 8). The annealing regions of 
the first primer pair are shown in red. b) Primer pairs used for the two consecutive PCR reactions. 
Primers of the first PCR contain a high complexity region to avoid problems of low-diversity 
sequencing. Primers of the second PCR contain barcodes for multiplex sequencing. Both primer 
pairs contain regions required for Illumina NextSeq sequencing. 
The plasmid DNA was obtained by infecting E. coli TG1 cells with the same peptide phage 
library, incubating the cells overnight in shaking cultures, and extracting the plasmid DNA. Two 
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consecutive PCR reactions were performed to prepare the DNA for NGS (Figure 29). In the first PCR 
reaction, the DNA coding for the random peptides in the library were amplified. In the second PCR 
reaction, primers were used that append a barcode to each different sample, allowing for multiplexed 
sequencing. The PCR products of all of the reactions were pooled, sequenced by the Illumina NextSeq 
500 instrument, and the sequences were sorted based on the barcode. Between 0.5 and 4 million reads 
were obtained for each data set, which was suitable for the analysis of samples with a diversity 
estimated to be smaller than 100,000 (Tables III and IV). Quality filters were applied to eliminate reads 
of poor quality and wrong length as described previously120. 
 Number of plasmids subjected to sequencing1 
 7 70 700 7000 70000 
Number of NGS reads2 1243589 653981 2269552 1416812 2049766 
Number of different peptides 75 6398 7597 50376 104325 
Number of different peptides with high abundance 12 55 450 4750 33000 
Calculated number of different peptides (a of eq. 2) 11 43 453 4109 33384 
Table III. NGS of plasmid DNA. 1Calculated based on absorption at 260 nm and the dilution 
factor. 2After applying a quality filter to remove reads with more than two bases with a quality score 
lower than Q18 and too-short or too-long peptides. 
 Number of phage subjected to sequencing1 
 7 70 700 7000 70000 
Number of NGS reads2 724779 1730575 2465070 1762376 481201 
Number of different peptides 64 7015 8365 60822 802011 
Number of different peptides with high abundance 9 90 650 5600 55000 
Calculated number of different peptides (a of eq. 2) 10 103 614 5569 67439 
Table IV. NGS of phage DNA. 1Calculated based on absorption at 260 nm and the dilution factor. 
2After applying a quality filter to remove reads with more than two bases with a quality score lower 
than Q18 and too-short or too-long peptides. 
?????? ????????????????????????????????????? ???
The NGS data was analyzed to quantify the number of different clones that were identified in 
each sample. The number of different clones in each sample was much larger than the number of 
clones that were prepared in the various dilutions (plasmid DNA or phage particle). Comparison of 
the sequences showed that for the most abundant peptides, a group of similar peptides was found that 
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differed in only one or a few amino acids (or bases). Such sequences are due to sequencing errors that 
occur in the NGS. A software tool was applied to correct sequences that differ by 6 or fewer bases120 
which substantially reduced the number of different clones. The peptides were then ordered based on 
their abundance and the copy number was plotted in graphs for each dilution of plasmid DNA (Figure 
30, left panels) and phage particle (Figure 31, left panels).  
 
Figure 30. Sequencing of plasmid DNA. Left panels: The graphs indicate how often each peptide 
was identified by NGS in a sample containing the indicated number of plasmids. The peptides are 
arranged according to their abundance. Right panels: Number of different sequences found when 
increasing numbers of reads were analyzed. Saturation plots were used for the calculation of the 
total number of different sequences, a of equation 2, shown in Table III. 
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Figure 31. Sequencing of ssDNA from phage particles. Left panels: The graphs indicate how 
often each peptide was identified by NGS in a sample containing the indicated number of plasmids. 
The peptides are arranged according to their abundance. Right panels: Number of different se-
quences found when increasing numbers of reads were analyzed. Saturation plots were used for the 
calculation of the total number of different sequences, a of equation 2, shown in Table IV. 
For all dilutions, an abundance distribution was found in which a small fraction of all identified 
clones showed a much higher copy number than the remaining clones. The two populations of high- 
and low-abundance clones can be distinguished visually by a sharp transition of the copy number. 
This transition is indicated in the graphs with a dashed line and the number of high-abundance clones 
is indicated as a number. Analysis of the low-abundance clones showed that they are mostly artefacts 
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arising from the multiplex sequencing where errors in barcode reading led to incorrect assignments. 
The number of high-abundance peptides thus provided a good estimate for the number of different 
clones that were identified within a sample. 
The number of clones identified in a sample can potentially be overestimated if clones 
containing sequencing errors were not filtered out completely and, consequently, appear as additional 
clones. If the number of distinct sequences (y) is plotted as a function of the total number of reads 
analyzed (x), the graph should show a curve that approaches the total number of different clones (a). 
The data can be fitted to equation 1 where k is a constant that depends on the abundance distribution 
of the sample. 
Equation 1:                                 ? ? ? ?? ? ????? 
If the sequencing errors are not fully filtered out, the number of distinct sequences is expected 
to continuously grow in a linear manner at large numbers of analyzed reads. In this case, the data can 
be fitted to equation 2 where b is the frequency of sequencing errors. 
Equation 2:                      ? ? ? ?? ? ????? ? ?? 
Fitting the data from the different samples to equation 2 (Figure 30 and 31, right panels) yielded 
values for the parameter b and revealed relatively low sequencing error rates between 1.7% and 6.2%. 
The number of different clones identified for the various samples, found by fitting the data to equation 
2, is shown in Tables III and IV. Due to the low error rate after filtering, these numbers do not deviate 
largely from those identified by counting the high-abundance clones in the graphs shown in the left 
panels of Figures 30 and 31. 
A comparison of the number of phage subjected to NGS sequencing and the number of 
identified peptide sequences shows that essentially all phage clones could be identified. The 
sequencing of DNA released from phage was as efficient as that of purified plasmid DNA, meaning 
that this technique could equivalently replace traditional phage display sequencing and has the 
advantage of being able to be used in situations in which bacterial infection is inefficient and 
sequencing from bacterial infections would not identify all clones. 
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5.4 – Conclusions 
In this study we show that essentially all clones in a sample of phage can be identified by se-
quencing the ssDNA that is released upon heating the phage particles in a PCR reaction. While 
ssDNA from phage particles has been used as a template for sequencing phage clones for a long time, 
the efficiency of the process was never accessed, and the number of clones that are actually able to be 
identified has never been counted. Our data show that the coverage of sequences is as good as the 
normal phage display sequencing technique – when phage are first transformed into bacterial cells, 
the DNA is extracted from cells or amplified phage, and the DNA is sequenced. Based on these results, 
the bacterial infection for DNA sequencing may be completely replaced by direct sequencing of 
ssDNA from phage particles, even in experiments with wild-type phage for which the infection step 
is efficient. The procedure of directly sequencing the ssDNA from phage particles is particularly at-
tractive for selections with phage that have a compromised infection capacity where only a fraction of 
phage-selected clones are able to infect bacterial cells in order to be identified in the sequencing step. 
This is, for example, the case for selections performed with phage that have a disulfide-free pIII or for 
selections in which chemical reagents are applied for peptide modification that impair the infectivity. 
This direct sequencing approach may even allow phage display with phage particles that have com-
pletely lost their ability to infect bacteria, greatly increasing the number of interesting modifications 
that can be performed using a phage library. 
5.5 – Materials and methods 
Peptide phage display library 
A peptide phage display library based on the vector fd-tet170 was used for all experiments. Phage of 
this library display random linear peptides of 14 amino acids encoded by NNK codons. The library 
comprises around 2.5 × 109 different peptides as estimated based on the number of colonies formed 
after transforming the library plasmid DNA into E. coli TG1 cells. Phage were produced by 
inoculating 0.5 L 2YT media containing 10 μg/mL tetracycline with library glycerol stock and growing 
the culture overnight at 30°C. Phage were purified by PEG precipitation as described previously and 
dissolved in water144. 
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Quantification of infective phage 
Ten-fold dilutions of phage were incubated with exponentially growing E. coli TG1 cells for 30 
minutes at 37°C without shaking, plated on 2YT agar plates containing tetracycline (10 μg/mL), and 
incubated at 37°C overnight. Colonies were counted and the transforming units (t.u.) were calculated. 
 
Quantification of phage particles 
The number of phage particles was quantified based on the optical density as described previously169. 
Dilutions of a phage solution containing 2 × 1013 t.u./mL were prepared, and the absorption at 269 
nm and 320 nm was measured. The number of phage particles was calculated using the following 
equation 3. The size of the fd-tet vector is 9.2 kb. 
Equation 3:      ????????????????? ? ?????????????? ???????????????????????????? 
In parallel, the number of phage particles was quantified by extracting the single-stranded phage DNA 
and measuring its optical density. A solution of phage containing 2 × 1013 t.u./mL was heated at 95°C 
for 10 min. The denatured capsid protein was removed by centrifugation at 10,000 g for 10 min at 
4°C. The absorbance at 260 nm was measured, and the number of phage particles was calculated using 
an extinction coefficient of 0.027 (μg/mL)-1.cm-1 for ssDNA. 
 
Phage and plasmid DNA quantification by qPCR 
Plasmid DNA was purified from E. coli glycerol stocks of the peptide phage display library (around 
50 mg of cell pellet) using a standard plasmid miniprep kit. The DNA was eluted from the columns 
with 50 μL of 5 mM Tris-Cl pH 8.5. The absorbance of the plasmid DNA at a wavelength of 260 nm 
was measured and the concentration calculated using an extinction coefficient of 0.02 (μg/mL)-1.cm-
1. 
Phage (7 × 1013 t.u./mL) and plasmid DNA (109 plasmids/mL) were diluted with water to obtain sam-
ples containing 105, 3.3 × 104, 1.1 × 104, 3.7 × 103, 1.2 × 103, 410, 140, 46, 15, and 5 molecules per μL 
(phage or plasmid DNA). The primer pair qPCRxd14f1 (5'-ATGGCAAACGCTAATAAG-3') / 
qPCRxd14r1 (5'-GTCACCAATGAAACCATC-3'), amplifying a region of 130 base pairs in the gene 
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of the phage pIII, and the TaqMan probe qPCRxd14p1 (FAM-ACCGTAATCAG-
TAGCGACAGAATCAA-BHQ1), annealing within the amplified region, were used for the detection 
of PCR DNA amplification by fluorescence. qPCR reactions were performed in a total volume of 10 
μL in MicroAmpTM optical 96-well reaction plates (ThermoFisher). The reagents were added in the 
following order to achieve the final concentrations indicated in brackets: 5 μL TaqMan Fast Advanced 
Master Mix, 0.8 μL of each primer (800 nM), 0.25 μL TaqMan probe (250 nM), 1 μL template (phage 
or plasmid DNA). A control reaction without template was included in each run. The reactions were 
run on a 7900HT Fast qPCR instrument. The thermal cycle conditions started with a 10 minute-long 
denaturation step at 95°C followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min each. The reac-
tions were performed in duplicate. 
 
Next-generation sequencing 
Dilutions of phage and plasmid DNA were prepared by diluting phage 10-fold with water. PCR 
reactions were prepared that contained 7, 70, 700, 7000, or 7 × 104 molecules of plasmid DNA or 
phage particles. The primers for the two PCR reactions were designed following the guidelines of the 
Nextera DNA Library Preparation Kit (Illumina). In the first reaction, the forward and reverse 
primers listed below were used. The part of the sequence that is underlined anneals with the template 
DNA. The region with the “N” repeats is a high complexity region that was inserted to avoid problems 
of low-diversity sequencing (in Illumina sequencing, the presence of many identical sequences yields 
sequencing images that pose a considerable challenge to the image recognition algorithm). The 5’-
regions of the primers contain sequences that are needed for Illumina sequencing. A 30 μL PCR 
reaction was performed by adding reagents in the following order to achieve the final concentrations 
indicated in brackets: 20.6 μL H2O, 6 μL 5× standard HF buffer, 0.9 μL DMSO, 0.6 μL dNTP (250 
μM), 0.6 μL primer mixture (the 10 primers were pre-mixed, 40 nM of each primer; 400 nM in total), 
0.3 μL Phusion® high-fidelity DNA polymerase (0.6 unit; New England Biolabs), and 1 μL phage or 
plasmid DNA. 25 PCR cycles were performed (98°C for 15 sec, 55°C for 30 sec, and 72°C for 15 sec). 
Formation of product was assessed by agarose gel electrophoresis (2.5%).  
Primers for 1st PCR reaction: 
NGS Forward1 5’-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGATTCTATGCGGCCCAGC-3' 
NGS Forward2 5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNATTCTATGCGGCCCAGC-3' 
NGS Forward3 5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNATTCTATGCGGCCCAGC-3' 
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NGS Forward4 5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNATTCTATGCGGCCCAGC-3' 
NGS Forward5 5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNATTCTATGCGGCCCAGC-3' 
NGS Reverse1 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGTTTCAGCGCCAGAACC-3' 
NGS Reverse2 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGNTTTCAGCGCCAGAACC-3' 
NGS Reverse3 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGNNTTTCAGCGCCAGAACC-3' 
NGS Reverse4 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGNNNTTTCAGCGCCAGAACC-3' 
NGS Reverse5 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGNNNNTTTCAGCGCCAGAACC-3' 
A second PCR was performed to append barcodes to the DNA to code for different samples and to 
append the DNA sequences required for Illumina sequencing. In the primers shown below, the 
regions of the barcodes are underlined. A 60 μL PCR reaction was performed by adding reagents in 
the following order to achieve the final concentrations indicated in brackets: 41.2 μL H2O, 12 μL 5x 
standard HF buffer, 1.8 μL DMSO, 1.2 μL dNTP (250 μM), 0.6 μL Phusion high-fidelity DNA 
polymerase (0.6 unit; New England Biolabs), 0.6 μL forward and reverse primer (400 nM), and 2 μL 
product of the 1st PCR. PCR products were purified from a 2.5% agarose gel (UltraPure agarose, 
Invitrogen) using a commercial agarose gel purification kit (QIAquick Gel Extraction Kit, Qiagen). 
DNA was eluted with 10 mM Tris-HCl, pH 8.5. Libraries were subsequently loaded at 1.5 pM on a 
Mid Output flow cell (Illumina) and sequenced with a NextSeq 500 instrument (Illumina) according 
to the manufacturer’s instructions, yielding paired-end reads of 75 nucleotides. Overlapping paired-
end reads were merged using CLC Genomics Workbench v9.5 (Qiagen). The DNA was sequenced 
along with at least 30% of unrelated non-amplicon-based libraries to avoid the low-diversity 
problems. 
Primer for 2nd PCR reaction: 
NGS 2nd Forward S507 5'-AATGATACGGCGACCACCGAGATCTACACAAGGAGTATCGTCGGCAGCGTC-3' 
NGS 2nd Forward S508 5'-AATGATACGGCGACCACCGAGATCTACACCTAAGCCTTCGTCGGCAGCGTC-3' 
NGS 2nd Forward S510 5'-AATGATACGGCGACCACCGAGATCTACACCGTCTAATTCGTCGGCAGCGTC-3' 
NGS 2nd Reverse N704 5'-CAAGCAGAAGACGGCATACGAGATGCTCAGGAGTCTCGTGGGCTCGG-3' 
NGS 2nd Reverse N705 5'-CAAGCAGAAGACGGCATACGAGATAGGAGTCCGTCTCGTGGGCTCGG-3' 
NGS 2nd Reverse N706 5'-CAAGCAGAAGACGGCATACGAGATCATGCCTAGTCTCGTGGGCTCGG-3' 
NGS 2nd Reverse N707 5'-CAAGCAGAAGACGGCATACGAGATGTAGAGAGGTCTCGTGGGCTCGG-3' 
NGS 2nd Reverse N714 5'-CAAGCAGAAGACGGCATACGAGATTCATGAGCGTCTCGTGGGCTCGG-3' 
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Processing of sequencing data 
Sequencing results were analyzed with previously developed MATLAB scripts120. In a first step, DNA 
reads and information about their quality were extracted from the .fastq file and saved in a .txt file 
using the MATLAB script Step1.m. In a second step, sequences were filtered to keep those with 
sufficient sequencing quality and the desired length, and translated into peptide sequences using the 
MATLAB script Step2.m that was modified as follows: the ACGTOnly parameter of the nt2aa 
function was set to “false” because Illumina sequencing returns ambiguous nucleotide characters (R, 
Y, K, M, S, W, B, D, H, V, and N). The script was executed using parameters to eliminate reads having 
more than two bases with a quality score lower than Q18 and reads coding for peptides that are too 
long or too short. In a third step, some of the remaining sequencing errors we corrected using the 
MATLAB script fixingerrors.m. Parameters were chosen such that this script recognized sequences 
that differ by 6 or fewer bases from the 1000 most abundant sequences. Such high sequence 
similarities were statistically unlikely and were interpreted as sequencing errors. 
 
Analysis of sequencing data 
The absolute number of different peptide sequences a was estimated by subtracting the number of 
sequences that were added through sequencing errors which could not be filtered or corrected by the 
procedures described above. The average error rate b was calculated by plotting the number of 
different peptide sequences y as a function of the number of analyzed reads x and fitting the data to 
equation 3 shown in the results section120. The different curves were plotted with GraphPad Prism 5 
(GraphPad software), and the coefficients a, b, and k were determined by non-linear regression.
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The first objective of my PhD was to set up a new method to increase the combinatorial 
diversity of bicyclic peptide libraries. In particular, we aimed to generate bicyclic peptide libraries that 
contain a high diversity of scaffolds. Although variation of the scaffold is the most important 
determinant of structural diversity, this has been prohibitively difficult to achieve in large 
combinatorial libraries up to now. Unfortunately, libraries with limited scaffold variation often result 
in poor screening outcomes due to incompatible interactions with their protein targets. To address 
this problem, we have conceived and developed a new strategy that provides rapid access to thousands 
of different macrocyclic scaffolds in libraries easy to synthesize, screen, and decode. The chosen 
approach was based on the use of bivalent linkers to cyclize peptides comprising four cysteines. To 
this end, my colleague, S. Kale, tested the ability of 12 structurally different chemical linkers to 
quantitatively and selectively link two pairs of cysteines in a model peptide. Nine linkers out of twelve 
reacted efficiently at concentrations that would not affect phage infectivity and propagation. In a 
proof of concept study, I applied six of these linkers to two phage-encoded libraries of bicyclic 
peptides (library 1: XCX3CX3CX and library 2: XCX4CX4CX) that were panned against the serine 
protease PK. As observed in prior studies, variation of the chemical linker had a strong effect on the 
sequence of the selected peptides81. In addition, our new approach led to the isolation of a peptide 
with 10-fold higher affinity than inhibitors developed by screening library 1 using the previous format 
with tri-functional linkers77. 
The great improvement of theoretical scaffold diversity has to be mitigated by the fact that 
not all double-bridged peptides will form on phage and strong isomer bias might occur. As seen on 
Figure 19, not all isomer are generated in the same proportion when cyclizing synthetic peptides. A 
similar result is expected for cyclization on phage. In addition, swapping the linker (Figure 22 and 23) 
often decreased the cyclization efficiency, peptide solubility and synthesis yield (data not shown). This 
implies that not all scaffolds can be easily formed and/or lead to well-behaved peptides in solution. 
However, even if only half of the possible scaffolds were forming, the library would still contain 37 
times more scaffolds than the former libraries with 3 cysteines. Finally, the bias for a specific isomer 
might lead to a more difficult identification of hits after phage selection. As observed on Figure 21, 
peptides with the best affinities are not always the most enriched in our selection. The fact that the 
most active isomer might not be the most represented on the five copies of pIII could be an 
explanation for this poor correlation between enrichement and KI. This limitation might be overcome 
by increasing the stringency of our affinity selections.  
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Target Associated disease/ 
application 
Affinity Project done 
by  
Factor XI Thrombotic diseases KI = 3 nM 
Dr. X Kong,  
V. Carle 
Interleukin 17  Chronic inflammatory and  
autoimmune diseases 
Kd = 32 nM Dr. X Kong 
Kallikrein-related 
peptidase 5 
 Netherton Syndrome (NS)  KI = 5 nM P. Gonschorek 
Kallikrein-related 
peptidase 7 
 Netherton Syndrome (NS)  KI = 50 nM P. Gonschorek 
FKBP12 
Point of care detection of 
FK506 
Kd = 18 nM C. Berti 
Table V. Affinity of double bridge bicyclic peptides isolated with our new method and 
libraries 
Though this work proved the feasibility of this method, our concept was not fully exploited 
because we used two pre-existing phage libraries that were tailored for cyclization with tri-functional 
linkers. Only around 20% of the clones in library 1 and 2 contained a fourth cysteine in one of the 
randomized positions. In addition, the fact that one of the central cysteines was fixed limited the 
overall scaffold diversity that could be generated with the double bridge strategy. Although 324 
peptide scaffolds were obtained after cyclization with the six chosen linkers, we anticipated that we 
could easily generate more than 7000 different scaffolds by varying the size of the peptides, changing 
the position of the central cysteines, and employing different linkers for cyclization. With this 
objective, two researchers of our laboratory, Dr Xudong Kong and Vanessa Carle, cloned new phage 
libraries comprising four cysteines (XCXmCXnCXoCX, with m+n+o = 3-8 in X. Kong’s library, and 
m+n+o = 12 in V. Carle’s library). The number of peptide sequences in each library was estimated 
around 1010, meaning that more than 1011 bicyclic peptides could potentially be generated by cyclizing 
with ten different linkers. These two different formats provide the peptides with different properties. 
In the library of V. Carle, the large size of the peptides is expected to lead to better interaction contacts 
between the ligand and its targets. Combined with the large peptide backbone diversity, this library 
has the potential to deliver ligands with high affinity and selectivity to difficult target classes, such as 
those involving protein-protein interactions. By contrast, X. Kong designed peptide libraries of 
shorter length that should theoretically be more resistant to proteolytic degradation. Our method and 
the new libraries have had an important impact on the future developments in our laboratory. More 
than seven different researchers are currently developing double bridged peptides by phage display. 
Binders have been isolated against a variety of targets (Table V). In all cases, phage selections with 
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these libraries have yielded peptides with nanomolar affinities to their targets that show great promise 
as therapeutic or diagnostic agents.   
Finally, the double bridge macrocycle format presented in this work is of particular interest 
to a larger research audience not only because it allows for the generation of better ligands to 
challenging targets but also because it is not limited to phage-encoded libraries and can be applied to 
any synthetic peptide, one-bead-one-compound or mRNA display library. 
  In my second project, my aim was to identify cyclic peptide ligands, using phage display 
technology, whose size would be small enough to promise potential intestinal absorption. Indeed,?the 
poor absorption of cyclic peptides in the gastronintestinal tract is a major limitation for their oral 
availability. Their large size and the numerous HBD present in amide bonds and in side chains 
typically prevent cell permeation. On the other hand, combining the properties of small size and high 
affinity in a cyclic peptide is difficult because fewer amino acids signifies fewer interactions with the 
target. In addition, phage displayed peptides are often cyclized via cysteine side chains which implies 
that two amino acid positions are not free for diversification and target interaction while contributing 
to the size and number of HBD. This can have a significant impact on the diversity of short cyclic 
peptide libraries. For example, in cyclic peptides of four or five amino acids, the number of variable 
amino acids is limited to two or three resulting in diversities of only 400 for peptides of the format 
CXXC and 8,000 for peptides of the form CXXXC. Such libraries are thus not likely to deliver ligands 
to any target. 
Recently, two new developments in our laboratory have enabled the creation of phage-
encoded libraries of small cyclic peptides that retain a relatively high diversity. The first is the 
establishment of a highly efficient peptide macrocyclization reaction in which a chemical linker reacts 
with the thiol group of a C-terminal cysteine and subsequently with the N-terminal amino group. 
With this reaction, only one amino acid side chain is absolutely required for the cyclization. As a 
result, in peptides containing four or five residues, three or four amino acid positions are free for 
diversification, which allows a diversity of 8,000 (XXXC) and 160,000 cyclic peptides (XXXXC), 
respectively. The second is the discovery of several linkers compatible with this thiol-to-amine 
cyclization, of which most were identified during the development of the double bridge strategy. 
Thus, more than 1.3 million different cyclic peptides of the format XXXC and XXXXC can be 
obtained if they are cyclized in parallel with the eight different reagents. I applied this strategy to 
selections against the two disease targets plasma kallikrein and coagulation factor XIa. This led to the 
identification of small thiol-to-amine cyclized pentapeptides with single-digit micromolar affinity. 
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As expected, the affinity of the selected peptides was more than one order of magnitude 
weaker than the affinity of other macrocyclic peptide inhibitors identified during phage selections 
with libraries containing longer peptides (PK6 = LCSLCCLRCA, KI  = 3.2 ± 0.5 nM; and FXI-X1 = 
ECSNIFCCRCP , KI  = 3 nM). These results highlight one limitation of using small cyclic peptide 
libraries. Nevertheless, this project gave valuable insight on what can be achieved with phage display 
technology. First, we proved that the thiol-to-amine cyclization was compatible with phage displayed 
peptides. This further expands the type of already known reactions that can be applied to cyclize phage 
displayed peptides. Second, we have isolated the smallest phage selected peptides known to date. 
However, the fact that peptides containing five amino acids were strongly enriched over those with 
four indicates that at least four side chains are needed for target engagement. Finally, the suboptimal 
affinities suggest that the chemical diversity conferred by the 20 canonical amino acids is too low to 
generate more potent binders. Thus, the thiol-to-amine strategy likely has greater potential to deliver 
peptides with high affinity when used in combinatorial strategies allowing the incorporation of non-
natural building blocks.  
As stated previously, cyclic peptides that are small, less polar, and resistant to proteases are 
more likely to be orally available. In this project, we addressed only the problem of the size. For 
instance, the two single digit micromolar inhibitors FXI7 and FXI8 (KI = 8.8 ± 1.5 μM and 7.4 ± 0.3 
μM, respectively) have a molecular mass below 700 Da. Although this is in line with our objectives, it 
is not sufficient to achieve oral availability. In particular, Nielsen et al. showed that the number of 
HBD is one of the most crucial parameter for oral availability of cyclic peptides124. Among the 125 
cyclic peptides reported in their review, only one compound with HBD > 6 shows an oral availability 
F > 10%.  Consequently, FXI7 and FXI8 contain too many HBD (HBD = 11 or 12) and the arginine 
alone accounts for 6 of them. A medicinal chemistry study aiming at reducing the polarity and 
mumber of HBD would be necessary to develop an orally available cyclic peptide. This may include 
modification of the side chains, N-methylation of the backbone etc. This problem has often been 
observed during the development of inhibitors for other trypsin-like serine proteases such as 
thrombin for which arginine mimetics or prodrug strategies were devised171,172. A similar approach 
could be applied to our peptides. 
In conclusion, further improvement of our peptides in terms of affinity, polarity and possibly 
stability would be required in order to develop a drug that has the potential to be orally administered. 
This represents a large medicinal chemistry effort that would take several months or years. For this 
reason, we decided to discontinue the development of these inhibitors and rather apply the thiol-to-
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amine cyclization to other combinatorial strategies that allow the incorporation of non-natural amino 
acids. 
 In my last project, I tested whether directly sequencing DNA from phage particles isolated 
after panning would be suitable to bypass the bacterial infection step in phage display. Therefore, we 
designed a study in which we showed that essentially all clones in a sample of phage could be identified 
by next generation sequencing of the ssDNA released upon heating the phage particles in a PCR 
reaction. Even a low amount of phage (< 100 particles) could be identified with this method, which is 
far below the typical amount of particles harvested after panning. This new method has not yet been 
employed for phage selection in our laboratory because standard procedures have shown to be robust 
enough for the type of coat protein mutations and post-translational modifications that we are 
currently using. In addition, applying only one round of selection would lead to a difficult isolation 
and identification of binders with desired characteristics. When large libraries are used, and therefore 
only few copies of any given binding phage clones are present, no obvious enrichment may be 
observed after a single round. Moreover, as stringency during the first round is generally low, 
relatively weak binders might be overrepresented. Therefore, our method is more likely to be useful 
for libraries having a small diversity and in cases where harsher genetic or chemical modifications 
disrupting the function of coat proteins are contemplated. 
?
?
 
? ?
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